Interleukin	B-protein
1beta	I-protein
mediates	O
the	O
modulatory	O
effects	O
of	O
monocytes	B-cell_type
on	O
LNCaP	B-cell_type
human	I-cell_type
prostate	I-cell_type
cancer	I-cell_type
cells	I-cell_type
.	O

Proliferative	O
and	O
secretory	O
responses	O
in	O
androgen-sensitive	B-cell_type
prostate	I-cell_type
cancer	I-cell_type
LNCaP	I-cell_type
cells	I-cell_type
are	O
regulated	O
by	O
steroid	O
and	O
peptide	O
hormones	O
and	O
by	O
differentiation-promoting	O
substances	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
whether	O
peripheral	B-cell_type
blood	I-cell_type
monocytes	I-cell_type
that	O
exhibit	O
anti-tumour	O
activity	O
in	O
haematopoietic	O
and	O
solid	O
tumours	O
influence	O
growth	O
and	O
secretion	O
in	O
the	O
LNCaP	B-cell_line
cell	I-cell_line
line	I-cell_line
.	O

For	O
this	O
purpose	O
,	O
LNCaP	B-cell_line
cells	I-cell_line
were	O
incubated	O
with	O
monocyte-conditioned	O
medium	O
(	O
MCM	O
)	O
,	O
and	O
proliferation	O
as	O
well	O
as	O
expression	O
of	O
androgen	B-protein
receptor	I-protein
(	O
AR	B-protein
)	O
and	O
secretion	O
of	O
prostate-specific	B-protein
antigen	I-protein
(	O
PSA	B-protein
)	O
were	O
assessed	O
.	O

Conditioned	O
medium	O
from	O
monocytes	B-cell_type
reduced	O
proliferation	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Incubation	O
with	O
40	O
%	O
MCM	O
caused	O
a	O
50	O
%	O
reduction	O
in	O
cell	O
proliferation	O
.	O

AR	B-protein
protein	I-protein
decreased	O
by	O
70	O
%	O
and	O
PSA	B-protein
levels	O
in	O
supernatants	O
from	O
LNCaP	B-cell_line
cells	I-cell_line
were	O
reduced	O
by	O
approximately	O
80	O
%	O
following	O
treatment	O
with	O
MCM	O
.	O

We	O
focused	O
on	O
the	O
contribution	O
of	O
two	O
major	O
products	O
of	O
activated	O
monocytes	B-cell_type
,	O
prostaglandin	O
E2	O
and	O
interleukin	B-protein
1beta	I-protein
(	O
IL-1beta	B-protein
)	O
,	O
to	O
the	O
MCM	O
modulatory	O
action	O
.	O

LNCaP	B-cell_line
cells	I-cell_line
treated	O
with	O
prostaglandin	O
E2	O
showed	O
neither	O
a	O
reduction	O
in	O
proliferation	O
nor	O
a	O
down-regulation	O
of	O
AR	B-protein
and	O
PSA	B-protein
levels	O
.	O

The	O
effects	O
of	O
MCM	O
on	O
cellular	O
proliferation	O
,	O
AR	B-protein
protein	I-protein
and	O
PSA	B-protein
secretion	O
were	O
abolished	O
by	O
pretreatment	O
of	O
MCM	O
with	O
a	O
neutralizing	O
anti-IL-1beta	B-protein
antibody	I-protein
.	O

In	O
addition	O
,	O
recombinant	O
IL-1beta	B-protein
was	O
able	O
to	O
replace	O
MCM	O
for	O
the	O
inhibition	O
of	O
proliferation	O
and	O
down-regulation	O
of	O
AR	B-protein
and	O
PSA	B-protein
proteins	O
.	O

LNCaP	B-cell_line
cells	I-cell_line
were	O
shown	O
to	O
express	O
the	O
IL-1beta	B-protein
receptor	O
type	O
1	O
,	O
which	O
transduces	O
IL-1beta	B-protein
signal	O
.	O

Our	O
findings	O
reveal	O
that	O
monocyte-derived	B-protein
IL-1beta	I-protein
inhibits	O
the	O
proliferation	O
of	O
androgen-responsive	B-cell_type
prostate	I-cell_type
tumour	I-cell_type
cells	I-cell_type
and	O
reduces	O
AR	B-protein
and	O
PSA	B-protein
levels	O
.	O

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
TB	NULL
(	NULL
8	NULL
)	NULL
.	NULL

1004-1011	NULL
©1998	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
Interleukin	NULL
168	NULL
mediates	NULL
the	NULL
modulatory	NULL
effects	NULL
of	NULL
monocytes	NULL
on	NULL
LNCaP	NULL
human	NULL
prostate	NULL
cancer	NULL
cells	NULL
Z	NULL
Culig	NULL
'	NULL
,	NULL
A	NULL
Hobisch	NULL
'	NULL
,	NULL
M	NULL
Herold	NULL
,	NULL
A	NULL
M	NULL
Thurnher	NULL
'	NULL
,	NULL
IE	NULL
Eder	NULL
,	NULL
MV	NULL
Cronauer	NULL
'	NULL
,	NULL
C	NULL
Rieser	NULL
'	NULL
,	NULL
R	NULL
Ramoner	NULL
'	NULL
,	NULL
G	NULL
Bartsch	NULL
'	NULL
,	NULL
H	NULL
Klocker	NULL
'	NULL
and	NULL
G	NULL
Konwalinka®	NULL
*Departments	NULL
of	NULL
Urology	NULL
.	NULL

``	NULL
Internal	NULL
Medicine	NULL
and	NULL
'Pathology	NULL
.	NULL

University	NULL
of	NULL
Innsbruck	NULL
.	NULL

Anichstrafe	NULL
35	NULL
.	NULL

A-6020	NULL
Innsbruck	NULL
.	NULL

Austria	NULL
Summary	NULL
Proliferative	NULL
and	NULL
secretory	NULL
responses	NULL
in	NULL
androgen-sensitive	NULL
prostate	NULL
cancer	NULL
LNCaP	NULL
cells	NULL
are	NULL
regulated	NULL
by	NULL
steroid	NULL
and	NULL
peptide	NULL
hormones	NULL
and	NULL
by	NULL
differentiation-promoting	NULL
substances	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
evaluated	NULL
whether	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
that	NULL
exhibit	NULL
anti-tumour	NULL
activity	NULL
in	NULL
haematopoietic	NULL
and	NULL
solid	NULL
tumours	NULL
influence	NULL
growth	NULL
and	NULL
secretion	NULL
in	NULL
the	NULL
LNCaP	NULL
cell	NULL
line	NULL
.	NULL

For	NULL
this	NULL
purpose	NULL
,	NULL
LNCaP	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
monocyte-conditioned	NULL
medium	NULL
(	NULL
MCM	NULL
)	NULL
,	NULL
and	NULL
proliferation	NULL
as	NULL
well	NULL
as	NULL
expression	NULL
of	NULL
androgen	NULL
receptor	NULL
(	NULL
AR	NULL
)	NULL
and	NULL
secretion	NULL
of	NULL
prostate-specific	NULL
antigen	NULL
(	NULL
PSA	NULL
)	NULL
were	NULL
assessed	NULL
.	NULL

Conditioned	NULL
medium	NULL
from	NULL
monocytes	NULL
reduced	NULL
proliferation	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
.	NULL

Incubation	NULL
with	NULL
40	NULL
%	NULL
MCM	NULL
caused	NULL
a	NULL
50	NULL
%	NULL
reduction	NULL
in	NULL
cell	NULL
proliferation	NULL
.	NULL

AR	NULL
protein	NULL
decreased	NULL
by	NULL
70	NULL
%	NULL
and	NULL
PSA	NULL
levels	NULL
in	NULL
supematants	NULL
from	NULL
LNCaP	NULL
cells	NULL
were	NULL
reduced	NULL
by	NULL
approximately	NULL
80	NULL
%	NULL
following	NULL
treatment	NULL
with	NULL
MCM	NULL
.	NULL

We	NULL
focused	NULL
on	NULL
the	NULL
contribution	NULL
of	NULL
two	NULL
major	NULL
products	NULL
of	NULL
activated	NULL
monocytes	NULL
,	NULL
prostaglandin	NULL
E	NULL
,	NULL
and	NULL
interleukin	NULL
16	NULL
(	NULL
IL-1B	NULL
)	NULL
.	NULL

to	NULL
the	NULL
MCM	NULL
modulatory	NULL
action	NULL
.	NULL

LNCaP	NULL
cells	NULL
treated	NULL
with	NULL
prostaglandin	NULL
E	NULL
,	NULL
showed	NULL
neither	NULL
a	NULL
reduction	NULL
in	NULL
proliferation	NULL
nor	NULL
a	NULL
down-regulation	NULL
of	NULL
AR	NULL
and	NULL
PSA	NULL
levels	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
MCM	NULL
on	NULL
cellular	NULL
proliferation	NULL
,	NULL
AR	NULL
protein	NULL
and	NULL
PSA	NULL
secretion	NULL
were	NULL
abolished	NULL
by	NULL
pretreatment	NULL
of	NULL
MCM	NULL
with	NULL
a	NULL
neutralizing	NULL
antibody	NULL
.	NULL

In	NULL
addition	NULL
.	NULL

recombinant	NULL
IL-1B	NULL
was	NULL
able	NULL
to	NULL
replace	NULL
MCM	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
proliferation	NULL
and	NULL
down-regulation	NULL
of	NULL
AR	NULL
and	NULL
PSA	NULL
proteins	NULL
.	NULL

LNCaP	NULL
cells	NULL
were	NULL
shown	NULL
to	NULL
express	NULL
the	NULL
IL-18	NULL
receptor	NULL
type	NULL
1	NULL
,	NULL
which	NULL
transduces	NULL
IL-1B	NULL
signal	NULL
.	NULL

Our	NULL
findings	NULL
reveal	NULL
that	NULL
monocyte-derived	NULL
IL-1f	NULL
inhibits	NULL
the	NULL
proliferation	NULL
of	NULL
androgen	NULL
responsive	NULL
prostate	NULL
tumour	NULL
cells	NULL
and	NULL
reduces	NULL
AR	NULL
and	NULL
PSA	NULL
levels	NULL
.	NULL

Keywords	NULL
:	NULL
prostate	NULL
cancer	NULL
cell	NULL
:	NULL
monocyte	NULL
:	NULL
proliferation	NULL
:	NULL
androgen	NULL
receptor	NULL
:	NULL
prostate-specific	NULL
antigen	NULL
:	NULL
interleukin	NULL
18	NULL
The	NULL
LNCaP	NULL
cell	NULL
line	NULL
.	NULL

which	NULL
was	NULL
derived	NULL
from	NULL
a	NULL
lymph	NULL
node	NULL
metastasis	NULL
of	NULL
a	NULL
patient	NULL
who	NULL
did	NULL
not	NULL
respond	NULL
to	NULL
endocrine	NULL
therapy	NULL
.	NULL

is	NULL
frequently	NULL
used	NULL
as	NULL
a	NULL
model	NULL
for	NULL
studying	NULL
human	NULL
prostate	NULL
cancer	NULL
(	NULL
Horoszewicz	NULL
et	NULL
al	NULL
.	NULL

1983	NULL
)	NULL
.	NULL

It	NULL
is	NULL
known	NULL
that	NULL
steroid	NULL
and	NULL
peptide	NULL
hormones	NULL
as	NULL
well	NULL
as	NULL
differentiation-promoting	NULL
substances	NULL
regulate	NULL
proliferative	NULL
and	NULL
secretory	NULL
responses	NULL
in	NULL
LNCaP	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
respond	NULL
to	NULL
androgen	NULL
stimulation	NULL
by	NULL
accelerating	NULL
division	NULL
and	NULL
producing	NULL
prostate-specific	NULL
antigen	NULL
(	NULL
PSA	NULL
)	NULL
.	NULL

The	NULL
pattems	NULL
of	NULL
andro-genic	NULL
regulation	NULL
of	NULL
growth	NULL
and	NULL
secretory	NULL
function	NULL
in	NULL
the	NULL
LNCaP	NULL
cell	NULL
line	NULL
are	NULL
different	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

The	NULL
maximal	NULL
growth	NULL
rate	NULL
is	NULL
achieved	NULL
at	NULL
0.1	NULL
nM	NULL
of	NULL
dihydrotestosterone	NULL
(	NULL
DHT	NULL
)	NULL
.	NULL

whereas	NULL
higher	NULL
doses	NULL
of	NULL
this	NULL
androgen	NULL
induce	NULL
growth	NULL
arrest	NULL
.	NULL

It	NULL
was	NULL
proposed	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
cellular	NULL
proliferation	NULL
by	NULL
high	NULL
androgen	NULL
doses	NULL
is	NULL
mediated	NULL
by	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
(	NULL
TGF-B	NULL
)	NULL
(	NULL
Kim	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
proliferative	NULL
response	NULL
.	NULL

the	NULL
percentage	NULL
of	NULL
PSA-positive	NULL
cells	NULL
and	NULL
the	NULL
levels	NULL
of	NULL
PSA	NULL
protein	NULL
in	NULL
LNCaP	NULL
supernatants	NULL
increase	NULL
at	NULL
concentrations	NULL
of	NULL
1	NULL
nM	NULL
dihydrotestosterone	NULL
and	NULL
beyond	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
androgens	NULL
.	NULL

polypeptide	NULL
growth	NULL
factors	NULL
such	NULL
as	NULL
epidermal	NULL
growth	NULL
factor	NULL
(	NULL
EGF	NULL
)	NULL
.	NULL

TGF-a	NULL
.	NULL

insulin-like	NULL
growth	NULL
factors	NULL
and	NULL
basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
(	NULL
bFGF	NULL
)	NULL
are	NULL
mitogenic	NULL
for	NULL
LNCaP	NULL
cells	NULL
(	NULL
Wilding	NULL
et	NULL
al	NULL
.	NULL

1989	NULL
;	NULL
MacDonald	NULL
and	NULL
Habib	NULL
.	NULL

1992	NULL
;	NULL
Nakamoto	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
;	NULL
Ritchie	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Positive	NULL
effects	NULL
of	NULL
tmiodothyronine	NULL
and	NULL
inhibitory	NULL
effects	NULL
of	NULL
vitamin	NULL
D.	NULL
retinoic	NULL
acid	NULL
.	NULL

luteinizing	NULL
hormone-releasing	NULL
hormone	NULL
.	NULL

phenylacetate	NULL
and	NULL
activin	NULL
on	NULL
growth	NULL
of	NULL
LNCaP	NULL
cells	NULL
have	NULL
also	NULL
Received	NULL
13	NULL
November	NULL
1997	NULL
Revised	NULL
17	NULL
March	NULL
1998	NULL
Accepted	NULL
19	NULL
March	NULL
1998	NULL
Correspondence	NULL
to	NULL
:	NULL
Z	NULL
Culig	NULL
1004	NULL
been	NULL
described	NULL
(	NULL
Limonta	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
;	NULL
Skowronski	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Young	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Esquenet	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Dalkin	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
:	NULL
Walls	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Secretion	NULL
of	NULL
PSA	NULL
was	NULL
found	NULL
to	NULL
be	NULL
enhanced	NULL
after	NULL
treatment	NULL
with	NULL
trnodothyronine	NULL
.	NULL

vitamin	NULL
D	NULL
and	NULL
phenylacetate	NULL
(	NULL
Skowronski	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Esquenet	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
;	NULL
Walls	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

whereas	NULL
divergent	NULL
results	NULL
on	NULL
PSA	NULL
regulation	NULL
by	NULL
retinoic	NULL
acid	NULL
were	NULL
reported	NULL
(	NULL
Fong	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
;	NULL
Young	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

LNCaP	NULL
cells	NULL
express	NULL
a	NULL
mutant	NULL
androgen	NULL
receptor	NULL
(	NULL
AR	NULL
)	NULL
.	NULL

which	NULL
binds	NULL
oestrogenic	NULL
and	NULL
progestagenic	NULL
steroids	NULL
and	NULL
non-steroidal	NULL
anti-androgens	NULL
hydroxyflutamide	NULL
and	NULL
nilutamide	NULL
with	NULL
higher	NULL
affinity	NULL
than	NULL
the	NULL
wild-type	NULL
AR	NULL
.	NULL

These	NULL
substances	NULL
induce	NULL
reporter	NULL
gene	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
LNCaP	NULL
AR	NULL
more	NULL
efficiently	NULL
than	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
wild-type	NULL
AR	NULL
(	NULL
Veldscholte	NULL
et	NULL
al	NULL
.	NULL

1990	NULL
)	NULL
.	NULL

Studies	NULL
on	NULL
interactions	NULL
between	NULL
leucocytes	NULL
that	NULL
produce	NULL
various	NULL
cytokines	NULL
and	NULL
differentiation	NULL
factors	NULL
and	NULL
prostate	NULL
tumour	NULL
cells	NULL
may	NULL
improve	NULL
understanding	NULL
of	NULL
prostate	NULL
cancer	NULL
biology	NULL
.	NULL

In	NULL
one	NULL
of	NULL
the	NULL
initial	NULL
studies	NULL
in	NULL
this	NULL
field	NULL
Hsieh	NULL
et	NULL
al	NULL
(	NULL
1995	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
phytohaemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
-stimulated	NULL
lymphocytes	NULL
produce	NULL
substance	NULL
(	NULL
s	NULL
)	NULL
that	NULL
reduce	NULL
cell	NULL
proliferation	NULL
.	NULL

increase	NULL
expression	NULL
of	NULL
cytoskeleton	NULL
proteins	NULL
and	NULL
down-regulate	NULL
AR	NULL
and	NULL
PSA	NULL
in	NULL
LNCaP	NULL
cells	NULL
.	NULL

These	NULL
effects	NULL
were	NULL
observed	NULL
after	NULL
treatment	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
T-lymphocyte-conditioned	NULL
media	NULL
(	NULL
TCM	NULL
)	NULL
.	NULL

However	NULL
.	NULL

the	NULL
T-cell-derived	NULL
factor	NULL
(	NULL
s	NULL
)	NULL
that	NULL
mediate	NULL
these	NULL
effects	NULL
have	NULL
so	NULL
far	NULL
not	NULL
been	NULL
identified	NULL
.	NULL

Interactions	NULL
between	NULL
other	NULL
cells	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
and	NULL
various	NULL
tumours	NULL
have	NULL
been	NULL
described	NULL
(	NULL
Wang	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
;	NULL
Iversen	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

For	NULL
example	NULL
.	NULL

monocytes	NULL
were	NULL
found	NULL
to	NULL
suppress	NULL
cell	NULL
viability	NULL
and	NULL
colony	NULL
formation	NULL
in	NULL
human	NULL
leukaemias	NULL
and	NULL
lung	NULL
tumours	NULL
.	NULL

In	NULL
this	NULL
study	NULL
.	NULL

we	NULL
address	NULL
the	NULL
issue	NULL
of	NULL
whether	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
influence	NULL
growth	NULL
and	NULL
secretion	NULL
in	NULL
androgen-responsive	NULL
prostatic	NULL
epithelial	NULL
cells	NULL
.	NULL

We	NULL
show	NULL
that	NULL
monocyte-derived	NULL
interleukin	NULL
1	NULL
(	NULL
IL-1	NULL
B	NULL
)	NULL
is	NULL
a	NULL
mediator	NULL
of	NULL
the	NULL
modulatory	NULL
effects	NULL
on	NULL
LNCaP	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Materials	NULL
MCDB-131	NULL
and	NULL
RPMI-1640	NULL
media	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
(	NULL
Deisenhofen	NULL
.	NULL

Germany	NULL
)	NULL
and	NULL
HyClone	NULL
(	NULL
Logan	NULL
.	NULL

UT	NULL
.	NULL

USA	NULL
)	NULL
respec-tively	NULL
.	NULL

Fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
and	NULL
antibiotics	NULL
(	NULL
penicillin/strepto-mycin	NULL
)	NULL
were	NULL
from	NULL
Biological	NULL
Industries	NULL
(	NULL
Kibutz	NULL
Beth	NULL
Haemek	NULL
.	NULL

Israel	NULL
)	NULL
.	NULL

Phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
was	NULL
from	NULL
PAA	NULL
Laboratories	NULL
(	NULL
Linz	NULL
.	NULL

Austria	NULL
)	NULL
.	NULL

Cell	NULL
culture	NULL
vessels	NULL
were	NULL
from	NULL
Costar	NULL
(	NULL
Cambridge	NULL
.	NULL

MA	NULL
.	NULL

USA	NULL
)	NULL
.	NULL

Sarstedt	NULL
(	NULL
Niimbrecht	NULL
.	NULL

Germany	NULL
)	NULL
and	NULL
Falcon	NULL
(	NULL
Lincoln	NULL
.	NULL

NE	NULL
.	NULL

USA	NULL
)	NULL
.	NULL

Phytohaemagglutinin-M	NULL
(	NULL
PHA-M	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
Difco	NULL
Laboratories	NULL
(	NULL
Detroit	NULL
.	NULL

MA	NULL
.	NULL

USA	NULL
)	NULL
.	NULL

The	NULL
murine	NULL
monoclonal	NULL
anti-cytokeratin	NULL
8	NULL
and	NULL
18	NULL
antibody	NULL
CAM	NULL
5.2	NULL
was	NULL
purchased	NULL
from	NULL
Becton	NULL
Dickinson	NULL
(	NULL
San	NULL
Jose	NULL
.	NULL

CA	NULL
.	NULL

USA	NULL
)	NULL
and	NULL
a	NULL
polyclonal	NULL
rabbit	NULL
anti-IL-1f	NULL
antibody	NULL
from	NULL
Genzyme	NULL
(	NULL
Cambridge	NULL
.	NULL

MA	NULL
.	NULL

USA	NULL
)	NULL
.	NULL

The	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
MEMI18	NULL
(	NULL
IgG1	NULL
anti-CD14	NULL
)	NULL
was	NULL
from	NULL
An	NULL
Der	NULL
Grub	NULL
.	NULL

Vienna	NULL
.	NULL

Austria	NULL
.	NULL

Biotinylated	NULL
monoclonal	NULL
antibody	NULL
6B5	NULL
(	NULL
IgG	NULL
?	NULL

a	NULL
anti-IL-1	NULL
receptor	NULL
type	NULL
I	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
PharMingen	NULL
(	NULL
San	NULL
Diego	NULL
.	NULL

CA	NULL
.	NULL

USA	NULL
)	NULL
.	NULL

Both	NULL
radiolabelled	NULL
(	NULL
specific	NULL
activity	NULL
83.2	NULL
Ci	NULL
mmol~	NULL
)	NULL
and	NULL
unlabelled	NULL
synthetic	NULL
androgen	NULL
methyltrienolone	NULL
(	NULL
R	NULL
1881	NULL
)	NULL
were	NULL
purchased	NULL
from	NULL
New	NULL
England	NULL
Nuclear	NULL
(	NULL
Dreieichenhain	NULL
.	NULL

Germany	NULL
)	NULL
.	NULL

IL-1B	NULL
was	NULL
provided	NULL
by	NULL
Sigma	NULL
.	NULL

Prostaglandin	NULL
E	NULL
,	NULL
was	NULL
from	NULL
Boehringer	NULL
Ingelheim	NULL
(	NULL
Heidelberg	NULL
.	NULL

Germany	NULL
)	NULL
.	NULL

The	NULL
scintillation	NULL
liquid	NULL
Optiphase	NULL
was	NULL
from	NULL
Pharmacia	NULL
(	NULL
Uppsala	NULL
.	NULL

Sweden	NULL
)	NULL
.	NULL

The	NULL
commercial	NULL
methyl-thiotetrazole	NULL
(	NULL
MTT	NULL
)	NULL
assay	NULL
E	NULL
,	NULL
ZU	NULL
was	NULL
purchased	NULL
from	NULL
Biomedica	NULL
(	NULL
Vienna	NULL
.	NULL

Austria	NULL
)	NULL
.	NULL

An	NULL
immunoenzymetric	NULL
assay	NULL
for	NULL
the	NULL
quantitative	NULL
measurement	NULL
of	NULL
human	NULL
IL-1	NULL
(	NULL
minimum	NULL
detectable	NULL
concentration	NULL
2	NULL
pg	NULL
ml~	NULL
'	NULL
)	NULL
was	NULL
provided	NULL
by	NULL
Medgenix	NULL
Diagnostics	NULL
(	NULL
Fleurus	NULL
.	NULL

Belgium	NULL
)	NULL
.	NULL

The	NULL
PSA	NULL
IMx	NULL
enzyme	NULL
immunoassay	NULL
(	NULL
sensitivity	NULL
0.1	NULL
ng	NULL
ml	NULL
)	NULL
was	NULL
from	NULL
Abbott	NULL
Laboratories	NULL
(	NULL
Abbott	NULL
Park	NULL
.	NULL

IL	NULL
.	NULL

USA	NULL
)	NULL
.	NULL

FACS	NULL
Calibur	NULL
apparatus	NULL
and	NULL
CellQuest	NULL
software	NULL
were	NULL
from	NULL
Becton-Dickinson	NULL
.	NULL

Culture	NULL
of	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
Peripheral	NULL
blood	NULL
was	NULL
collected	NULL
from	NULL
three	NULL
healthy	NULL
volunteers	NULL
on	NULL
several	NULL
occasions	NULL
.	NULL

Monocytes	NULL
were	NULL
obtained	NULL
from	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
after	NULL
Ficoll	NULL
separation	NULL
by	NULL
standard	NULL
adherence	NULL
(	NULL
90	NULL
min	NULL
.	NULL

37°C	NULL
)	NULL
and	NULL
cultured	NULL
in	NULL
RPMI-1640	NULL
medium	NULL
that	NULL
was	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
charcoal-stripped	NULL
FCS	NULL
(	NULL
CS	NULL
FCS	NULL
)	NULL
.	NULL

The	NULL
purity	NULL
of	NULL
monocytes	NULL
as	NULL
determined	NULL
by	NULL
staining	NULL
for	NULL
naphthol	NULL
acetate	NULL
esterase	NULL
and	NULL
by	NULL
measuring	NULL
CD14	NULL
expression	NULL
was	NULL
>	NULL
90	NULL
%	NULL
.	NULL

For	NULL
preparation	NULL
of	NULL
monocyte-conditioned	NULL
medium	NULL
(	NULL
MCM	NULL
)	NULL
.	NULL

2.5	NULL
x	NULL
1	NULL
(	NULL
¢	NULL
monocytes	NULL
ml-	NULL
were	NULL
cultured	NULL
with	NULL
and	NULL
without	NULL
PHA	NULL
.	NULL

After	NULL
48	NULL
h.	NULL
the	NULL
supernatants	NULL
were	NULL
cleared	NULL
by	NULL
centrifugation	NULL
and	NULL
frozen	NULL
at	NULL
-	NULL
20°C	NULL
until	NULL
use	NULL
.	NULL

Proliferation	NULL
assays	NULL
in	NULL
LNCaP	NULL
cells	NULL
The	NULL
LNCaP	NULL
cell	NULL
line	NULL
was	NULL
purchased	NULL
at	NULL
passage	NULL
21	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Bethesda	NULL
.	NULL

MD	NULL
.	NULL

USA	NULL
)	NULL
.	NULL

LNCaP	NULL
cells	NULL
were	NULL
seeded	NULL
into	NULL
24-well	NULL
plates	NULL
at	NULL
2	NULL
x	NULL
10¢	NULL
cells	NULL
per	NULL
well	NULL
in	NULL
MCDB-131	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
.	NULL

Medium	NULL
was	NULL
changed	NULL
24	NULL
h	NULL
later	NULL
and	NULL
the	NULL
final	NULL
concentration	NULL
of	NULL
CS	NULL
FCS	NULL
was	NULL
3	NULL
%	NULL
.	NULL

Culture	NULL
medium	NULL
was	NULL
supplemented	NULL
with	NULL
MCM	NULL
(	NULL
10-60	NULL
%	NULL
)	NULL
.	NULL

©	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
1998	NULL
Interleukin-18	NULL
effects	NULL
on	NULL
prostate	NULL
tumour	NULL
cells	NULL
1005	NULL
prostaglandin	NULL
E.	NULL
(	NULL
1-10	NULL
um	NULL
or	NULL
IL-1B	NULL
(	NULL
0.1-10	NULL
ng	NULL
ml-	NULL
)	NULL
.	NULL

Control	NULL
experiments	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
any	NULL
supplement	NULL
in	NULL
medium	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
PHA-M	NULL
.	NULL

In	NULL
neutralization	NULL
experiments	NULL
.	NULL

MCM	NULL
was	NULL
preincubated	NULL
with	NULL
the	NULL
antibody	NULL
against	NULL
IL-1fB	NULL
overnight	NULL
.	NULL

It	NULL
has	NULL
previously	NULL
been	NULL
determined	NULL
that	NULL
1	NULL
mg	NULL
of	NULL
this	NULL
antibody	NULL
is	NULL
capable	NULL
of	NULL
neutralizing	NULL
approximately	NULL
1000	NULL
units	NULL
of	NULL
natural	NULL
or	NULL
recombinant	NULL
IL-1B	NULL
.	NULL

Cell	NULL
proliferation	NULL
was	NULL
determined	NULL
after	NULL
72	NULL
h	NULL
incubation	NULL
by	NULL
means	NULL
of	NULL
the	NULL
MTT	NULL
assay	NULL
.	NULL

This	NULL
assay	NULL
is	NULL
based	NULL
on	NULL
the	NULL
ability	NULL
of	NULL
living	NULL
cells	NULL
to	NULL
reduce	NULL
slightly	NULL
coloured	NULL
tetrazolium	NULL
salts	NULL
to	NULL
intensely	NULL
coloured	NULL
formazan	NULL
derivatives	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
Cronauer	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

In	NULL
selected	NULL
experiments	NULL
the	NULL
MTT	NULL
assay	NULL
results	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
obtained	NULL
with	NULL
a	NULL
cell	NULL
counter	NULL
and	NULL
were	NULL
found	NULL
to	NULL
be	NULL
identical	NULL
.	NULL

immunohistochemical	NULL
analyses	NULL
Following	NULL
treatment	NULL
with	NULL
MCM	NULL
or	NULL
medium	NULL
without	NULL
supplements	NULL
.	NULL

LNCaP	NULL
cells	NULL
were	NULL
trypsinized	NULL
.	NULL

cytospun	NULL
.	NULL

resuspended	NULL
in	NULL
PBS	NULL
.	NULL

fixed	NULL
in	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
.	NULL

permeabilized	NULL
by	NULL
adding	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
and	NULL
stained	NULL
for	NULL
cyokeratin	NULL
expression	NULL
.	NULL

Cytokeratin	NULL
immunohistochemistry	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
a	NULL
strepta-vidin-biotin-peroxidase	NULL
protocol	NULL
.	NULL

The	NULL
immunohistochemical	NULL
procedure	NULL
was	NULL
described	NULL
previously	NULL
(	NULL
Hobisch	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Androgen	NULL
receptor-binding	NULL
assay	NULL
LNCaP	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
untreated	NULL
control	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
respective	NULL
supplements	NULL
in	NULL
5	NULL
%	NULL
CS	NULL
FCS	NULL
for	NULL
72	NULL
h.	NULL
Then	NULL
they	NULL
were	NULL
scraped	NULL
off	NULL
.	NULL

washed	NULL
once	NULL
.	NULL

resuspended	NULL
in	NULL
medium	NULL
and	NULL
incubated	NULL
with	NULL
[	NULL
'HJmethylItrienolone	NULL
.	NULL

at	NULL
concentrations	NULL
of	NULL
0.3-5	NULL
ny	NULL
.	NULL

for	NULL
90	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Non-specific	NULL
binding	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabelled	NULL
methyItrienolone	NULL
.	NULL

The	NULL
pellets	NULL
were	NULL
recovered	NULL
after	NULL
incubation	NULL
by	NULL
centrifugation	NULL
(	NULL
3800	NULL
g.	NULL
3	NULL
min	NULL
)	NULL
and	NULL
washed	NULL
twice	NULL
with	NULL
500	NULL
pul	NULL
of	NULL
ice-cold	NULL
medium	NULL
.	NULL

The	NULL
cell	NULL
pellets	NULL
were	NULL
then	NULL
lysed	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
scin-tilation	NULL
liquid	NULL
and	NULL
the	NULL
radioactivity	NULL
was	NULL
determined	NULL
in	NULL
a	NULL
B-counter	NULL
.	NULL

Cellular	NULL
protein	NULL
was	NULL
determined	NULL
according	NULL
to	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Bradford	NULL
(	NULL
1978	NULL
)	NULL
.	NULL

B__	NULL
and	NULL
K	NULL
,	NULL
were	NULL
calculated	NULL
by	NULL
Scatchard	NULL
analysis	NULL
.	NULL

~	NULL
Determination	NULL
of	NULL
prostate-specific	NULL
antigen	NULL
in	NULL
supernatants	NULL
from	NULL
LNCaP	NULL
cells	NULL
The	NULL
cells	NULL
were	NULL
grown	NULL
on	NULL
24-well	NULL
plates	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
5	NULL
%	NULL
CS	NULL
FCS	NULL
with	NULL
or	NULL
without	NULL
supplements	NULL
.	NULL

The	NULL
medium	NULL
was	NULL
removed	NULL
after	NULL
72	NULL
h	NULL
and	NULL
the	NULL
PSA	NULL
level	NULL
was	NULL
measured	NULL
by	NULL
an	NULL
enzyme	NULL
immunoassay	NULL
.	NULL

PSA	NULL
values	NULL
were	NULL
corrected	NULL
for	NULL
cell	NULL
number	NULL
according	NULL
to	NULL
the	NULL
results	NULL
of	NULL
the	NULL
proliferation	NULL
assay	NULL
.	NULL

Determination	NULL
of	NULL
IL-1B	NULL
concentration	NULL
in	NULL
monocyte	NULL
conditioned	NULL
media	NULL
IL-18B	NULL
in	NULL
MCM	NULL
was	NULL
determined	NULL
by	NULL
a	NULL
solid-phase	NULL
enzyme	NULL
amplified	NULL
sensitivity	NULL
immunoassay	NULL
.	NULL

The	NULL
assay	NULL
is	NULL
based	NULL
on	NULL
an	NULL
oligoclonal	NULL
system	NULL
in	NULL
which	NULL
several	NULL
monoclonal	NULL
antibodies	NULL
directed	NULL
against	NULL
distinct	NULL
epitopes	NULL
of	NULL
IL-1B	NULL
are	NULL
used	NULL
.	NULL

The	NULL
use	NULL
of	NULL
several	NULL
distinct	NULL
monoclonal	NULL
antibodies	NULL
avoids	NULL
assay	NULL
hyperspecificity	NULL
.	NULL

The	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
a	NULL
microtitre	NULL
plate	NULL
.	NULL

Samples	NULL
containing	NULL
IL-1f	NULL
react	NULL
with	NULL
capture	NULL
antibodies	NULL
coated	NULL
on	NULL
a	NULL
plastic	NULL
well	NULL
and	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
labelled	NULL
with	NULL
horseradish	NULL
peroxidase	NULL
.	NULL

After	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
78	NULL
(	NULL
8	NULL
)	NULL
.	NULL

1004-1011	NULL
1006	NULL
Z	NULL
Culig	NULL
et	NULL
al	NULL
A	NULL
200	NULL
160	NULL
120	NULL
Cell	NULL
number	NULL
200	NULL
160	NULL
120	NULL
foc	NULL
T	NULL
J	NULL
acca	NULL
fills	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
10°	NULL
Fluorescence	NULL
intensity	NULL
Figure	NULL
1	NULL
-	NULL
Phenotypic	NULL
characterization	NULL
of	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
and	NULL
LNCaP	NULL
cells	NULL
.	NULL

Monocytes	NULL
(	NULL
A	NULL
)	NULL
and	NULL
LNCaP	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
were	NULL
labelled	NULL
with	NULL
monocional	NULL
antibodies	NULL
specific	NULL
for	NULL
the	NULL
antigen	NULL
indicated	NULL
followed	NULL
by	NULL
FITC-conjugated	NULL
secondary	NULL
antibody	NULL
.	NULL

and	NULL
surface	NULL
expression	NULL
(	NULL
bold	NULL
lines	NULL
)	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
flow	NULL
cytometer	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
methods	NULL
.	NULL

isotype-matched	NULL
antibodies	NULL
were	NULL
included	NULL
as	NULL
controls	NULL
(	NULL
dotted	NULL
lines	NULL
)	NULL
.	NULL

Fluorescence	NULL
intensity	NULL
(	NULL
x-axis	NULL
)	NULL
is	NULL
plotted	NULL
against	NULL
the	NULL
number	NULL
of	NULL
cells	NULL
(	NULL
y-axis	NULL
)	NULL
an	NULL
incubation	NULL
period	NULL
of	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
the	NULL
microtitre	NULL
plate	NULL
was	NULL
washed	NULL
three	NULL
times	NULL
to	NULL
remove	NULL
unbound	NULL
enzyme-labelled	NULL
antibodies	NULL
.	NULL

The	NULL
revelation	NULL
solution	NULL
-	NULL
(	NULL
tetramethylbenzydine-hydrogen	NULL
peroxide	NULL
)	NULL
was	NULL
added	NULL
and	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
reaction	NULL
was	NULL
stopped	NULL
with	NULL
sulphuric	NULL
acid	NULL
and	NULL
the	NULL
microtitre	NULL
plate	NULL
was	NULL
read	NULL
at	NULL
450	NULL
nm	NULL
.	NULL

The	NULL
concentrations	NULL
of	NULL
in	NULL
MCM	NULL
ranged	NULL
between	NULL
1.6	NULL
and	NULL
2.4	NULL
ng	NULL
ml-	NULL
'	NULL
.	NULL

Measurement	NULL
of	NULL
surface	NULL
antigen	NULL
expression	NULL
by	NULL
flow	NULL
cytometry	NULL
To	NULL
determine	NULL
surface	NULL
antigen	NULL
expression	NULL
.	NULL

peripheral	NULL
blood	NULL
monocytes	NULL
were	NULL
labelled	NULL
with	NULL
primary	NULL
mouse	NULL
monoclonal	NULL
anti-CDI14	NULL
antibody	NULL
MEM18	NULL
followed	NULL
by	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
FITC	NULL
)	NULL
-conjugated	NULL
goat	NULL
anti-mouse	NULL
Ig	NULL
.	NULL

LNCaP	NULL
cells	NULL
were	NULL
labelled	NULL
with	NULL
biotinylated	NULL
primary	NULL
mouse	NULL
monoclonal	NULL
anti-IL-1	NULL
receptor	NULL
antibody	NULL
6B5	NULL
followed	NULL
by	NULL
FITC-conjugated	NULL
streptavidin	NULL
.	NULL

Washes	NULL
were	NULL
in	NULL
PBS	NULL
containing	NULL
0.2	NULL
%	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
.	NULL

After	NULL
the	NULL
last	NULL
wash.	NULL
the	NULL
cells	NULL
were	NULL
stored	NULL
in	NULL
PBS	NULL
containing	NULL
0.2	NULL
%	NULL
BSA	NULL
and	NULL
2	NULL
%	NULL
formaldehyde	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
analysed	NULL
on	NULL
a	NULL
FACS	NULL
Calibur	NULL
.	NULL

Data	NULL
were	NULL
analysed	NULL
and	NULL
presented	NULL
using	NULL
CellQuest	NULL
software	NULL
.	NULL

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
78	NULL
(	NULL
8	NULL
)	NULL
.	NULL

1004-1011	NULL
Figure	NULL
2	NULL
.	NULL

Morphology	NULL
of	NULL
untreated	NULL
(	NULL
A	NULL
)	NULL
and	NULL
MCM-treated	NULL
(	NULL
B	NULL
)	NULL
LNCaP	NULL
cells	NULL
.	NULL

MCM	NULL
-treated	NULL
cells	NULL
are	NULL
elongated	NULL
and	NULL
exhibit	NULL
dendrite-like	NULL
processes	NULL
.	NULL

which	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
(	NULL
original	NULL
magnification	NULL
x	NULL
100	NULL
)	NULL
RESULTS	NULL
Monocyte-conditioned	NULL
medium-treated	NULL
LNCaP	NULL
cells	NULL
show	NULL
changes	NULL
in	NULL
cell	NULL
shape	NULL
To	NULL
study	NULL
the	NULL
influence	NULL
of	NULL
monocytes	NULL
on	NULL
prostate	NULL
cancer	NULL
cells	NULL
.	NULL

LNCaP	NULL
cells	NULL
were	NULL
exposed	NULL
to	NULL
medium	NULL
conditioned	NULL
by	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
homogenously	NULL
positive	NULL
for	NULL
CD14	NULL
(	NULL
Figure	NULL
1A	NULL
)	NULL
.	NULL

Distinct	NULL
morphological	NULL
changes	NULL
in	NULL
LNCaP	NULL
cells	NULL
were	NULL
observed	NULL
after	NULL
treatment	NULL
with	NULL
monocyte-conditioned	NULL
medium	NULL
(	NULL
MCM	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
became	NULL
elongated	NULL
and	NULL
showed	NULL
dendrite-like	NULL
processes	NULL
.	NULL

which	NULL
were	NULL
connected	NULL
to	NULL
each	NULL
other	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

These	NULL
morphological	NULL
changes	NULL
were	NULL
notable	NULL
even	NULL
with	NULL
10	NULL
%	NULL
MCM	NULL
in	NULL
LNCaP	NULL
culture	NULL
medium	NULL
.	NULL

Expression	NULL
of	NULL
cytoskeletal	NULL
proteins	NULL
was	NULL
evaluated	NULL
by	NULL
semiquantitative	NULL
immunohistochemistry	NULL
.	NULL

A	NULL
monoclonal	NULL
antibody	NULL
directed	NULL
against	NULL
luminal	NULL
cytokeratins	NULL
8	NULL
and	NULL
18	NULL
was	NULL
used	NULL
for	NULL
this	NULL
purpose	NULL
.	NULL

The	NULL
expression	NULL
and	NULL
staining	NULL
intensity	NULL
of	NULL
these	NULL
cytokeratins	NULL
were	NULL
previously	NULL
reported	NULL
to	NULL
increase	NULL
in	NULL
the	NULL
more	NULL
differentiated	NULL
prostatic	NULL
luminal	NULL
epithelium	NULL
(	NULL
PeehI	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
LNCaP	NULL
cells	NULL
treated	NULL
with	NULL
MCM	NULL
.	NULL

we	NULL
observed	NULL
neither	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
percentage	NULL
of	NULL
cytokeratin-immunopositive	NULL
cells	NULL
nor	NULL
a	NULL
change	NULL
in	NULL
staining	NULL
intensity	NULL
.	NULL

©	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
1998	NULL
150	NULL
100	NULL
Proliferation	NULL
(	NULL
%	NULL
)	NULL
on	NULL
&	NULL
|	NULL
0	NULL
--	NULL
0	NULL
3	NULL
3	NULL
3	NULL
p33	NULL
s	NULL
I3	NULL
O	NULL
o	NULL
[	NULL
6	NULL
]	NULL
o	NULL
c	NULL
c	NULL
Q	NULL
ps3	NULL
p33	NULL
3	NULL
3	NULL
©	NULL
SE	NULL
6	NULL
fas	NULL
fs	NULL
fas	NULL
3	NULL
sO	NULL
-	NULL
a	NULL
&	NULL
#	NULL
5	NULL
34	NULL
Q	NULL
6	NULL
a	NULL
O	NULL
Figure	NULL
3	NULL
-	NULL
The	NULL
effects	NULL
of	NULL
increasing	NULL
concentrations	NULL
of	NULL
MCM	NULL
on	NULL
proliferation	NULL
of	NULL
LNCaP	NULL
cells	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
MCM	NULL
for	NULL
72	NULL
h	NULL
and	NULL
cell	NULL
proliferation	NULL
was	NULL
assessed	NULL
by	NULL
the	NULL
colorimetric	NULL
MT	NULL
T	NULL
assay	NULL
.	NULL

Four	NULL
measurements	NULL
were	NULL
performed	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
in	NULL
per	NULL
cent	NULL
of	NULL
untreated	NULL
cells	NULL
,	NULL
which	NULL
were	NULL
set	NULL
at	NULL
100	NULL
%	NULL
.	NULL

Mean	NULL
values	NULL
and	NULL
standard	NULL
deviations	NULL
were	NULL
calculated	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
,	NULL
MCM	NULL
treatment	NULL
vs	NULL
untreated	NULL
cells	NULL
(	NULL
0	NULL
)	NULL
and	NULL
R1881	NULL
+	NULL
MCM	NULL
vs	NULL
R1881	NULL
,	NULL
Mann-Whitney	NULL
U-test	NULL
Monocyte-conditioned	NULL
medium	NULL
causes	NULL
a	NULL
dose-dependent	NULL
reduction	NULL
in	NULL
cellular	NULL
proliferation	NULL
LNCaP	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
MCM	NULL
for	NULL
3	NULL
days	NULL
.	NULL

After	NULL
this	NULL
period	NULL
,	NULL
cellular	NULL
growth	NULL
was	NULL
assessed	NULL
by	NULL
means	NULL
of	NULL
the	NULL
MTT	NULL
assay	NULL
.	NULL

Conditioned	NULL
medium	NULL
from	NULL
PHA-M-activated	NULL
monocytes	NULL
reduced	NULL
cellular	NULL
proliferation	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

MCM	NULL
at	NULL
40	NULL
%	NULL
reduced	NULL
proliferation	NULL
by	NULL
50	NULL
%	NULL
.	NULL

Higher	NULL
concentrations	NULL
of	NULL
MCM	NULL
in	NULL
culture	NULL
media	NULL
did	NULL
not	NULL
result	NULL
in	NULL
any	NULL
further	NULL
reduction	NULL
in	NULL
cell	NULL
number	NULL
.	NULL

PHA-M	NULL
itself	NULL
did	NULL
not	NULL
display	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
proliferation	NULL
of	NULL
LNCaP	NULL
cells	NULL
.	NULL

Conditioned	NULL
medium	NULL
from	NULL
monocytes	NULL
that	NULL
were	NULL
not	NULL
treated	NULL
with	NULL
PHA-M	NULL
induced	NULL
a	NULL
similar	NULL
decrease	NULL
in	NULL
cell	NULL
proliferation	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
it	NULL
seems	NULL
that	NULL
the	NULL
presence	NULL
of	NULL
PHA	NULL
in	NULL
monocyte	NULL
cultures	NULL
is	NULL
not	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
growth	NULL
of	NULL
LNCaP	NULL
cells	NULL
.	NULL

The	NULL
proliferative	NULL
effect	NULL
of	NULL
0.01	NULL
nm	NULL
of	NULL
R1881	NULL
was	NULL
abolished	NULL
by	NULL
40	NULL
%	NULL
MCM	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

Androgen	NULL
receptor	NULL
levels	NULL
and	NULL
PSA	NULL
secretion	NULL
decrease	NULL
after	NULL
treatment	NULL
with	NULL
MCM	NULL
Specific	NULL
binding	NULL
of	NULL
radioactively	NULL
labelled	NULL
methyltrienolone	NULL
in	NULL
MCM-treated	NULL
LNCaP	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
controls	NULL
was	NULL
determined	NULL
.	NULL

MCM	NULL
caused	NULL
a	NULL
dose-dependent	NULL
reduction	NULL
in	NULL
androgen	NULL
binding	NULL
.	NULL

Figure	NULL
4	NULL
shows	NULL
a	NULL
decrease	NULL
in	NULL
specific	NULL
binding	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
JR1881	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
40	NULL
%	NULL
MCM	NULL
.	NULL

The	NULL
maximum	NULL
decrease	NULL
in	NULL
the	NULL
AR	NULL
level	NULL
was	NULL
approximately	NULL
70	NULL
%	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
40	NULL
%	NULL
MCM	NULL
.	NULL

There	NULL
was	NULL
no	NULL
change	NULL
in	NULL
AR	NULL
binding	NULL
affinity	NULL
following	NULL
MCM	NULL
treatment	NULL
.	NULL

Secretion	NULL
of	NULL
the	NULL
AR-regulated	NULL
PSA	NULL
protein	NULL
was	NULL
measured	NULL
in	NULL
supernatants	NULL
from	NULL
LNCaP	NULL
cells	NULL
after	NULL
72	NULL
h	NULL
of	NULL
incubation	NULL
with	NULL
©	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
1998	NULL
Interleukin-1	NULL
$	NULL
effects	NULL
on	NULL
prostate	NULL
tumour	NULL
cells	NULL
1007	NULL
12	NULL
10	NULL
7	NULL
[	NULL
5	NULL
]	NULL
&	NULL
2	NULL
x	NULL
8	NULL
7	NULL
3	NULL
o	NULL
.	NULL

3	NULL
2	NULL
6-7	NULL
ke	NULL
!	NULL

5	NULL
D	NULL
0	NULL
8	NULL
4-®	NULL
a	NULL
0	NULL
4	NULL
T	NULL
T	NULL
i	NULL
T	NULL
T	NULL
I	NULL
o	NULL
1	NULL
2	NULL
3	NULL
a	NULL
5	NULL
6	NULL
PH	NULL
]	NULL
R1881	NULL
(	NULL
nm	NULL
)	NULL
Figure	NULL
4	NULL
-	NULL
Methyltriencione	NULL
binding	NULL
in	NULL
untreated	NULL
(	NULL
control	NULL
)	NULL
and	NULL
MCM-treated	NULL
LNCaP	NULL
cells	NULL
.	NULL

After	NULL
72	NULL
h	NULL
of	NULL
MCM	NULL
treatment	NULL
,	NULL
LNCaP	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
90	NULL
min	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-methyltrienolone	NULL
.	NULL

Non-specific	NULL
binding	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
200-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabelled	NULL
methyltrienolone	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
ice-cold	NULL
medium	NULL
and	NULL
specific	NULL
binding	NULL
was	NULL
determined	NULL
.	NULL

O	NULL
,	NULL
Control	NULL
,	NULL
K	NULL
,	NULL
=	NULL
1.1	NULL
nmol	NULL
,	NULL
B	NULL
...	NULL
,	NULL
=	NULL
0.60	NULL
fmol	NULL
ug~*	NULL
protein	NULL
;	NULL
CJ	NULL
,	NULL
40	NULL
%	NULL
MCM	NULL
,	NULL
K	NULL
,	NULL
=	NULL
1.0	NULL
nmol	NULL
,	NULL
B.	NULL
,	NULL
,	NULL
=	NULL
0.16	NULL
fmol	NULL
ug=	NULL
'	NULL
protein	NULL
MCM	NULL
.	NULL

A	NULL
decrease	NULL
in	NULL
PSA	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
20-40	NULL
%	NULL
of	NULL
MCM	NULL
in	NULL
culture	NULL
media	NULL
.	NULL

PSA	NULL
protein	NULL
was	NULL
reduced	NULL
by	NULL
80	NULL
%	NULL
with	NULL
40	NULL
%	NULL
MCM	NULL
.	NULL

MCM	NULL
also	NULL
antagonized	NULL
stimulatory	NULL
effects	NULL
of	NULL
the	NULL
synthetic	NULL
androgen	NULL
R1881	NULL
on	NULL
PSA	NULL
secretion	NULL
into	NULL
the	NULL
super-natant	NULL
(	NULL
Figure	NULL
5	NULL
)	NULL
.	NULL

IL-1§	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
modulatory	NULL
effects	NULL
of	NULL
MCM	NULL
We	NULL
focused	NULL
on	NULL
the	NULL
contribution	NULL
of	NULL
individual	NULL
factors	NULL
to	NULL
the	NULL
MCM	NULL
modulatory	NULL
effects	NULL
.	NULL

Initially	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
role	NULL
of	NULL
prostaglandin	NULL
E	NULL
,	NULL
,	NULL
which	NULL
is	NULL
a	NULL
major	NULL
product	NULL
of	NULL
activated	NULL
monocytes	NULL
(	NULL
Venkataprasad	NULL
et	NULL
al	NULL
,	NULL
1996	NULL
)	NULL
.	NULL

LNCaP	NULL
cells	NULL
treated	NULL
with	NULL
prostaglandin	NULL
E	NULL
,	NULL
showed	NULL
neither	NULL
a	NULL
reduction	NULL
in	NULL
proliferation	NULL
nor	NULL
a	NULL
down-regulation	NULL
of	NULL
AR	NULL
and	NULL
PSA	NULL
levels	NULL
.	NULL

Thus	NULL
,	NULL
prostaglandin	NULL
E	NULL
,	NULL
can	NULL
be	NULL
excluded	NULL
as	NULL
a	NULL
mediator	NULL
of	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
monocytes	NULL
on	NULL
androgen-responsive	NULL
prostate	NULL
cancer	NULL
cells	NULL
.	NULL

Next	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
role	NULL
of	NULL
the	NULL
proinflammatory	NULL
cytokine	NULL
IL-1	NULL
}	NULL
,	NULL
which	NULL
exhibits	NULL
anti-tumour	NULL
activity	NULL
in	NULL
several	NULL
models	NULL
(	NULL
Kilian	NULL
et	NULL
al	NULL
,	NULL
1991	NULL
;	NULL
Braunschweiger	NULL
et	NULL
al	NULL
,	NULL
1996	NULL
)	NULL
,	NULL
in	NULL
the	NULL
interaction	NULL
between	NULL
the	NULL
immune	NULL
system	NULL
and	NULL
prostate	NULL
cancer	NULL
cells	NULL
.	NULL

In	NULL
order	NULL
to	NULL
determine	NULL
whether	NULL
IL-1	NULL
B	NULL
mediates	NULL
MCM	NULL
effects	NULL
on	NULL
LNCaP	NULL
cells	NULL
,	NULL
MCM	NULL
was	NULL
preincubated	NULL
with	NULL
a	NULL
neutralizing	NULL
polyclonal	NULL
anti-IL-1f	NULL
}	NULL
antibody	NULL
.	NULL

The	NULL
effectiveness	NULL
of	NULL
this	NULL
antibody	NULL
was	NULL
previously	NULL
demonstrated	NULL
in	NULL
other	NULL
assay	NULL
systems	NULL
(	NULL
Salem	NULL
et	NULL
al	NULL
,	NULL
1990	NULL
;	NULL
Lisak	NULL
and	NULL
Bealmear	NULL
,	NULL
1991	NULL
)	NULL
.	NULL

MCM	NULL
pretreated	NULL
with	NULL
the	NULL
antibody	NULL
did	NULL
not	NULL
reduce	NULL
LNCaP	NULL
cell	NULL
proliferation	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

The	NULL
MCM	NULL
effect	NULL
on	NULL
AR	NULL
protein	NULL
was	NULL
completely	NULL
abolished	NULL
after	NULL
preincubation	NULL
of	NULL
MCM	NULL
with	NULL
the	NULL
polyclonal	NULL
anti-IL-1B	NULL
antibody	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
,	NULL
and	NULL
the	NULL
PSA	NULL
levels	NULL
were	NULL
almost	NULL
completely	NULL
restored	NULL
(	NULL
Figure	NULL
6C	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
addition	NULL
of	NULL
recombinant	NULL
IL-1f	NULL
}	NULL
to	NULL
cultures	NULL
of	NULL
LNCaP	NULL
cells	NULL
exerted	NULL
effects	NULL
that	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
78	NULL
(	NULL
8	NULL
)	NULL
,	NULL
1004-1011	NULL
1008	NULL
Z	NULL
Culig	NULL
et	NULL
al	NULL
15	NULL
=	NULL
PSA	NULL
(	NULL
ng	NULL
UA	NULL
'	NULL
)	NULL
p3	NULL
o	NULL
<	NULL
Pe	NULL
6	NULL
a	NULL
30	NULL
%	NULL
MCM	NULL
40	NULL
%	NULL
MCM	NULL
0.01	NULL
nm	NULL
R1881	NULL
0.01	NULL
nm	NULL
R1881+	NULL
40	NULL
%	NULL
MCM	NULL
0.1	NULL
nm	NULL
R1881	NULL
0.1	NULL
nm	NULL
R1881+	NULL
40	NULL
%	NULL
MCM	NULL
Figure	NULL
5	NULL
-	NULL
Regulation	NULL
of	NULL
PSA	NULL
secretion	NULL
in	NULL
LNCaP	NULL
cells	NULL
by	NULL
MCM	NULL
.	NULL

The	NULL
celis	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
MCM	NULL
for	NULL
72	NULL
h.	NULL
PSA	NULL
levels	NULL
were	NULL
measured	NULL
by	NULL
an	NULL
enzyme	NULL
immunoassay	NULL
and	NULL
normalized	NULL
according	NULL
to	NULL
cell	NULL
proliferation	NULL
as	NULL
assessed	NULL
by	NULL
means	NULL
of	NULL
the	NULL
MTT	NULL
assay	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
nanograms	NULL
of	NULL
PSA	NULL
per	NULL
unit	NULL
of	NULL
absorbance	NULL
at	NULL
450	NULL
nm	NULL
(	NULL
UA	NULL
)	NULL
.	NULL

Mean	NULL
values	NULL
and	NULL
standard	NULL
deviations	NULL
were	NULL
calculated	NULL
from	NULL
four	NULL
independent	NULL
experiments	NULL
.	NULL

*P	NULL
<	NULL
0.05	NULL
.	NULL

MCM	NULL
treatment	NULL
vs	NULL
untreated	NULL
cells	NULL
(	NULL
0	NULL
)	NULL
and	NULL
R1881	NULL
+	NULL
MCM	NULL
vs	NULL
R1881	NULL
.	NULL

Mann-Whitney	NULL
U-test	NULL
were	NULL
almost	NULL
identical	NULL
to	NULL
those	NULL
of	NULL
MCM	NULL
.	NULL

Cell	NULL
proliferation	NULL
was	NULL
reduced	NULL
dose	NULL
dependently	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
.	NULL

the	NULL
AR	NULL
protein	NULL
levels	NULL
decreased	NULL
(	NULL
Figure	NULL
6D	NULL
)	NULL
and	NULL
PSA	NULL
secretion	NULL
was	NULL
diminished	NULL
(	NULL
Figure	NULL
6C	NULL
)	NULL
.	NULL

Finally	NULL
.	NULL

LNCaP	NULL
cells	NULL
were	NULL
shown	NULL
to	NULL
express	NULL
the	NULL
IL-1B	NULL
receptor	NULL
type	NULL
I	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

which	NULL
transduces	NULL
IL-1	NULL
$	NULL
signal	NULL
(	NULL
Curtis	NULL
et	NULL
al	NULL
.	NULL

1989	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
major	NULL
finding	NULL
of	NULL
the	NULL
present	NULL
study	NULL
is	NULL
that	NULL
peripheral	NULL
blood	NULL
monocytes	NULL
are	NULL
capable	NULL
of	NULL
modulating	NULL
cellular	NULL
events	NULL
in	NULL
androgen-responsive	NULL
LNCaP	NULL
cells	NULL
by	NULL
secreting	NULL
IL-1B	NULL
.	NULL

This	NULL
ability	NULL
of	NULL
monocytes	NULL
is	NULL
similar	NULL
to	NULL
that	NULL
previously	NULL
reported	NULL
for	NULL
T	NULL
lymphocytes	NULL
in	NULL
the	NULL
same	NULL
cell	NULL
line	NULL
(	NULL
Hsieh	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Both	NULL
cell	NULL
types	NULL
secrete	NULL
substances	NULL
that	NULL
cause	NULL
a	NULL
reduction	NULL
in	NULL
cellular	NULL
proliferation	NULL
.	NULL

diminish	NULL
levels	NULL
of	NULL
AR	NULL
protein	NULL
and	NULL
down-regulate	NULL
PSA	NULL
in	NULL
LNCaP	NULL
cells	NULL
.	NULL

In	NULL
our	NULL
experiments	NULL
.	NULL

MCM	NULL
was	NULL
effective	NULL
regardless	NULL
of	NULL
the	NULL
presence	NULL
of	NULL
PHA	NULL
in	NULL
monocyte	NULL
cultures	NULL
.	NULL

In	NULL
contrast	NULL
.	NULL

unstimulated	NULL
lymphocytes	NULL
provoked	NULL
only	NULL
a	NULL
minimal	NULL
growth	NULL
inhibition	NULL
of	NULL
LNCaP	NULL
cells	NULL
(	NULL
Hsieh	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

LNCaP	NULL
cells	NULL
became	NULL
elongated	NULL
and	NULL
exhibited	NULL
dendrite-like	NULL
processes	NULL
after	NULL
contact	NULL
with	NULL
MCM	NULL
and	NULL
TCM	NULL
.	NULL

Similar	NULL
changes	NULL
in	NULL
cell	NULL
shape	NULL
were	NULL
described	NULL
after	NULL
treatment	NULL
of	NULL
LNCaP	NULL
cells	NULL
with	NULL
analogues	NULL
of	NULL
cAMP	NULL
(	NULL
Bang	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

There	NULL
was	NULL
.	NULL

however	NULL
.	NULL

one	NULL
difference	NULL
between	NULL
MCM-	NULL
and	NULL
TCM-treated	NULL
LNCaP	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
cytokeratins	NULL
8	NULL
and	NULL
18	NULL
and	NULL
their	NULL
staining	NULL
intensity	NULL
increased	NULL
twofold	NULL
after	NULL
incubation	NULL
with	NULL
TCM	NULL
as	NULL
determined	NULL
by	NULL
a	NULL
total	NULL
intensity	NULL
score	NULL
procedure	NULL
(	NULL
Hsieh	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
MCM	NULL
we	NULL
did	NULL
not	NULL
see	NULL
any	NULL
differences	NULL
in	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
78	NULL
(	NULL
8	NULL
)	NULL
.	NULL

1004-1011	NULL
cytoskeleton	NULL
proteins	NULL
by	NULL
semiquantitative	NULL
immunohistochemistry	NULL
.	NULL

Contrasting	NULL
results	NULL
on	NULL
expression	NULL
of	NULL
cytokeratins	NULL
may	NULL
be	NULL
due	NULL
to	NULL
use	NULL
of	NULL
different	NULL
antibodies	NULL
and	NULL
immunohistochemical	NULL
techniques	NULL
.	NULL

It	NULL
was	NULL
suggested	NULL
by	NULL
others	NULL
that	NULL
TCM-	NULL
and	NULL
cAMP	NULL
analogue-treated	NULL
LNCaP	NULL
cells	NULL
undergo	NULL
neuroendocrine	NULL
differentiation	NULL
(	NULL
Bang	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Hsieh	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

TCM	NULL
treatment	NULL
provoked	NULL
an	NULL
increase	NULL
in	NULL
total	NULL
intensity	NULL
score	NULL
of	NULL
two	NULL
neuroendocrine	NULL
markers	NULL
.	NULL

neuron-specific	NULL
enolase	NULL
and	NULL
serotonin	NULL
.	NULL

However	NULL
.	NULL

the	NULL
concept	NULL
of	NULL
neuroendocrine	NULL
differentiation	NULL
of	NULL
this	NULL
cell	NULL
line	NULL
was	NULL
questioned	NULL
recently	NULL
(	NULL
Noordzij	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

In	NULL
that	NULL
publication	NULL
and	NULL
in	NULL
our	NULL
previous	NULL
experimental	NULL
studies	NULL
neuroendocrine	NULL
cells	NULL
within	NULL
the	NULL
LNCaP	NULL
cell	NULL
line	NULL
were	NULL
not	NULL
identified	NULL
(	NULL
unpublished	NULL
data	NULL
)	NULL
.	NULL

Thus	NULL
.	NULL

a	NULL
differentiation	NULL
process	NULL
induced	NULL
by	NULL
leucocytes	NULL
in	NULL
androgen-responsive	NULL
prostate	NULL
cancer	NULL
cells	NULL
is	NULL
not	NULL
well	NULL
characterized	NULL
to	NULL
date	NULL
.	NULL

The	NULL
MCM-induced	NULL
growth-inhibitory	NULL
effect	NULL
was	NULL
associated	NULL
with	NULL
decreased	NULL
AR	NULL
expression	NULL
.	NULL

Association	NULL
between	NULL
AR	NULL
expression	NULL
and	NULL
growth	NULL
regulation	NULL
of	NULL
prostate	NULL
cancer	NULL
cells	NULL
can	NULL
be	NULL
studied	NULL
in	NULL
AR-positive	NULL
LNCaP	NULL
cells	NULL
and	NULL
in	NULL
AR	NULL
cDNA-transfected	NULL
PC-3	NULL
cells	NULL
.	NULL

It	NULL
was	NULL
demonstrated	NULL
that	NULL
the	NULL
expression	NULL
of	NULL
AR	NULL
in	NULL
PC-3	NULL
cells	NULL
leads	NULL
to	NULL
a	NULL
decrease	NULL
in	NULL
proliferation	NULL
(	NULL
Yuan	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
.	NULL

We	NULL
infer	NULL
that	NULL
more	NULL
reliable	NULL
information	NULL
on	NULL
AR	NULL
involvement	NULL
in	NULL
growth	NULL
regulation	NULL
may	NULL
be	NULL
obtained	NULL
in	NULL
its	NULL
natural	NULL
cellular	NULL
environment	NULL
.	NULL

i.e	NULL
.	NULL

in	NULL
LNCaP	NULL
cells	NULL
.	NULL

Growth	NULL
inhibition	NULL
and	NULL
AR	NULL
reduction	NULL
were	NULL
previously	NULL
observed	NULL
in	NULL
LNCaP	NULL
cells	NULL
incubated	NULL
with	NULL
retinoic	NULL
acid	NULL
and	NULL
TCM	NULL
(	NULL
Young	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Hsieh	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Regarding	NULL
AR	NULL
expression	NULL
.	NULL

conditioned	NULL
media	NULL
from	NULL
T	NULL
lymphocytes	NULL
and	NULL
monocytes	NULL
.	NULL

and	NULL
retinoic	NULL
acid	NULL
differ	NULL
from	NULL
anti-androgens	NULL
cyproterone	NULL
acetate	NULL
.	NULL

hydroxyflutamide	NULL
and	NULL
bicalutamide	NULL
.	NULL

which	NULL
are	NULL
commonly	NULL
used	NULL
in	NULL
endocrine	NULL
therapy	NULL
for	NULL
prostate	NULL
cancer	NULL
.	NULL

These	NULL
compounds	NULL
bind	NULL
to	NULL
the	NULL
AR	NULL
with	NULL
low	NULL
affinity	NULL
and	NULL
do	NULL
not	NULL
permit	NULL
acquisition	NULL
of	NULL
a	NULL
tran-scriptionally	NULL
active	NULL
form	NULL
of	NULL
the	NULL
receptor	NULL
(	NULL
Kemppainen	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
;	NULL
Kallio	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

However	NULL
.	NULL

they	NULL
did	NULL
not	NULL
down-regulate	NULL
AR	NULL
protein	NULL
itself	NULL
.	NULL

AR	NULL
is	NULL
expressed	NULL
in	NULL
relapsed	NULL
prostate	NULL
tumours	NULL
and	NULL
in	NULL
their	NULL
metastases	NULL
.	NULL

which	NULL
were	NULL
obtained	NULL
before	NULL
onset	NULL
of	NULL
therapy	NULL
and	NULL
durning	NULL
tumour	NULL
progression	NULL
(	NULL
van	NULL
der	NULL
Kwast	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
;	NULL
Hobisch	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Several	NULL
recent	NULL
publications	NULL
support	NULL
the	NULL
view	NULL
that	NULL
reduction	NULL
in	NULL
androgen	NULL
concentration	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
prevent	NULL
transmission	NULL
of	NULL
extracellular	NULL
signals	NULL
via	NULL
the	NULL
AR	NULL
(	NULL
Veldscholte	NULL
et	NULL
al	NULL
.	NULL

1990	NULL
;	NULL
Culig	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
.	NULL

1994	NULL
;	NULL
Kokontis	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Nazareth	NULL
and	NULL
Weigel	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Prostate	NULL
cancer	NULL
cells	NULL
may	NULL
adapt	NULL
to	NULL
an	NULL
environment	NULL
with	NULL
very	NULL
low	NULL
androgen	NULL
concentration	NULL
by	NULL
increasing	NULL
their	NULL
AR	NULL
expression	NULL
and	NULL
transcriptional	NULL
activity	NULL
(	NULL
Kokontis	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
)	NULL
.	NULL

Furthermore	NULL
.	NULL

mutant	NULL
ARs	NULL
discovered	NULL
in	NULL
prostate	NULL
cancer	NULL
frequently	NULL
exhibit	NULL
a	NULL
gain	NULL
in	NULL
function	NULL
:	NULL
they	NULL
are	NULL
efficiently	NULL
activated	NULL
by	NULL
other	NULL
steroids	NULL
and	NULL
non-steroidal	NULL
AR	NULL
antagonists	NULL
(	NULL
Veldscholte	NULL
et	NULL
al	NULL
.	NULL

1990	NULL
:	NULL
Culig	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
.	NULL

Finally	NULL
.	NULL

AR	NULL
activity	NULL
is	NULL
up-regulated	NULL
by	NULL
several	NULL
non-steroidal	NULL
substances	NULL
such	NULL
as	NULL
polypeptide	NULL
growth	NULL
factors	NULL
and	NULL
second	NULL
messengers	NULL
(	NULL
Culig	NULL
et	NULL
al	NULL
.	NULL

1994	NULL
;	NULL
Nazareth	NULL
and	NULL
Weigel	NULL
.	NULL

1996	NULL
)	NULL
.	NULL

Therefore	NULL
.	NULL

strategies	NULL
aimed	NULL
at	NULL
reducing	NULL
AR	NULL
levels	NULL
.	NULL

such	NULL
as	NULL
administration	NULL
of	NULL
secretory	NULL
products	NULL
from	NULL
the	NULL
immune	NULL
cells	NULL
.	NULL

may	NULL
be	NULL
beneficial	NULL
in	NULL
metastatic	NULL
prostate	NULL
cancer	NULL
.	NULL

AR	NULL
down-regulation	NULL
was	NULL
followed	NULL
by	NULL
reduction	NULL
of	NULL
PSA	NULL
protein	NULL
in	NULL
LNCaP	NULL
supernatants	NULL
.	NULL

Thus	NULL
.	NULL

the	NULL
effect	NULL
of	NULL
MCM	NULL
is	NULL
different	NULL
to	NULL
that	NULL
of	NULL
phenvlacetate	NULL
and	NULL
vitamin	NULL
D.	NULL
substances	NULL
that	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
inhibit	NULL
proliferation	NULL
of	NULL
LNCaP	NULL
cells	NULL
and	NULL
increase	NULL
PSA	NULL
secretion	NULL
(	NULL
Walls	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
:	NULL
Zhao	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

The	NULL
mediator	NULL
role	NULL
of	NULL
IL-1	NULL
B	NULL
was	NULL
revealed	NULL
in	NULL
experiments	NULL
in	NULL
which	NULL
the	NULL
neutralizing	NULL
anti-IL-1B	NULL
antibody	NULL
abolished	NULL
the	NULL
effects	NULL
of	NULL
MCM	NULL
.	NULL

Furthermore	NULL
.	NULL

IL-1	NULL
itself	NULL
exhibited	NULL
a	NULL
dose-dependent	NULL
inhibition	NULL
on	NULL
LNCaP	NULL
proliferation	NULL
.	NULL

AR	NULL
protein	NULL
level	NULL
and	NULL
PSA	NULL
secretion	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
our	NULL
findings	NULL
with	NULL
MCM	NULL
.	NULL

a	NULL
compound	NULL
that	NULL
is	NULL
responsible	NULL
©	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
1998	NULL
A	NULL
125-*	NULL
*	NULL
1007	NULL
T	NULL
T	NULL
C	NULL
&	NULL
T	NULL
$	NULL
C	NULL
c	NULL
o	NULL
3	NULL
u	NULL
5	NULL
D	NULL
I	NULL
5	NULL
g	NULL
0	NULL
To	NULL
10	NULL
f	NULL
O1	NULL
1	NULL
x	NULL
3	NULL
T	NULL
T	NULL
>	NULL
C	NULL
TL	NULL
O	NULL
a	NULL
9	NULL
e	NULL
E	NULL
i	NULL
E	NULL
E	NULL
o	NULL
&	NULL
-	NULL
l=	NULL
n	NULL
Ps	NULL
C	NULL
_	NULL
&	NULL
[	NULL
<	NULL
o	NULL
T	NULL
3	NULL
iD	NULL
~	NULL
<	NULL
o	NULL
o	NULL
=	NULL
)	NULL
C	NULL
o	NULL
B	NULL
12-7	NULL
10	NULL
7	NULL
5	NULL
3	NULL
-	NULL
8	NULL
x	NULL
a	NULL
TC	NULL
o	NULL
674	NULL
&	NULL
£	NULL
€	NULL
2	NULL
9	NULL
so	NULL
4	NULL
9	NULL
9	NULL
a	NULL
t	NULL
2	NULL
0	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
i	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
H	NULL
]	NULL
R1881	NULL
nw	NULL
)	NULL
Interleukin-18	NULL
effects	NULL
on	NULL
prostate	NULL
tumour	NULL
cells	NULL
1009	NULL
C	NULL
*	NULL
*	NULL
*	NULL
<	NULL
D	NULL
&	NULL
E	NULL
<	NULL
w	NULL
a.	NULL
o	NULL
M	NULL
=	NULL
.	NULL

CD	NULL
=	NULL
=	NULL
a	NULL
§	NULL
0	NULL
f	NULL
%	NULL
T	NULL
f	NULL
3	NULL
+	NULL
-	NULL
!	NULL

-	NULL
_	NULL
x	NULL
3	NULL
~	NULL
ee	NULL
TL	NULL
&	NULL
9	NULL
E	NULL
l	NULL
-	NULL
E	NULL
T	NULL
2°	NULL
o	NULL
_	NULL
)	NULL
E	NULL
o	NULL
xt	NULL
E	NULL
_	NULL
o	NULL
C	NULL
9	NULL
g	NULL
E	NULL
3	NULL
~	NULL
o	NULL
be	NULL
E	NULL
o	NULL
6	NULL
D	NULL
12	NULL
=	NULL
10	NULL
5	NULL
]	NULL
3	NULL
-	NULL
8	NULL
x	NULL
€	NULL
a	NULL
Z	NULL
a	NULL
67	NULL
&	NULL
§	NULL
€	NULL
4	NULL
o	NULL
9	NULL
a	NULL
t	NULL
2	NULL
0	NULL
I	NULL
1	NULL
I	NULL
I	NULL
I	NULL
I	NULL
0	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
[	NULL
°H	NULL
]	NULL
R1881	NULL
(	NULL
nw	NULL
Figure	NULL
6	NULL
-	NULL
The	NULL
effects	NULL
of	NULL
pretreatment	NULL
of	NULL
MCM	NULL
with	NULL
the	NULL
neutralizing	NULL
polyclonal	NULL
anti-lL-13	NULL
antibody	NULL
and	NULL
the	NULL
effects	NULL
of	NULL
IL-13	NULL
on	NULL
(	NULL
A	NULL
)	NULL
proliferation	NULL
.	NULL

(	NULL
B	NULL
.	NULL

D	NULL
)	NULL
cellular	NULL
AR	NULL
protein	NULL
levels	NULL
and	NULL
(	NULL
C	NULL
)	NULL
PSA	NULL
protein	NULL
in	NULL
supernatants	NULL
of	NULL
LNCaP	NULL
cells	NULL
.	NULL

Four	NULL
independent	NULL
experiments	NULL
were	NULL
performed	NULL
.	NULL

(	NULL
AB	NULL
.	NULL

antibody	NULL
)	NULL
:	NULL
A	NULL
.	NULL

C	NULL
*P	NULL
<	NULL
0.05	NULL
.	NULL

IL-13	NULL
treatment	NULL
vs	NULL
untreated	NULL
cells	NULL
(	NULL
0	NULL
)	NULL
and	NULL
antibody	NULL
pretreatment	NULL
vs	NULL
treatment	NULL
without	NULL
antibody	NULL
.	NULL

Mann-Whitney	NULL
U-test	NULL
.	NULL

B	NULL
.	NULL

D	NULL
:	NULL
_	NULL
.	NULL

Control	NULL
.	NULL

K.	NULL
=	NULL
1.0	NULL
nmol	NULL
.	NULL

B.	NULL
,	NULL
,	NULL
=	NULL
0.62	NULL
fmol	NULL
ug~	NULL
protein	NULL
:	NULL
2	NULL
.	NULL

40°	NULL
:	NULL
MCM	NULL
.	NULL

K	NULL
,	NULL
=	NULL
1.6	NULL
nmol	NULL
.	NULL

B_	NULL
,	NULL
,	NULL
=	NULL
0.19	NULL
fmol	NULL
ug-	NULL
protein	NULL
:	NULL
#	NULL
.	NULL

40	NULL
%	NULL
MCM	NULL
+	NULL
AB	NULL
.	NULL

K.	NULL
=	NULL
1.2	NULL
nmol	NULL
.	NULL

8_	NULL
,	NULL
,	NULL
=	NULL
6.60	NULL
fmol	NULL
ug	NULL
protein	NULL
for	NULL
the	NULL
growth-modulatory	NULL
effects	NULL
of	NULL
TCM	NULL
on	NULL
androgen-responsive	NULL
prostate	NULL
cancer	NULL
cells	NULL
has	NULL
not	NULL
been	NULL
identified	NULL
.	NULL

Antibodies	NULL
against	NULL
TNF-	NULL
@	NULL
.	NULL

TGF-B	NULL
.	NULL

FGF	NULL
.	NULL

EGF	NULL
and	NULL
IL-2	NULL
.	NULL

-4	NULL
.	NULL

-5	NULL
.	NULL

-6	NULL
or	NULL
-8	NULL
were	NULL
tested	NULL
.	NULL

but	NULL
none	NULL
of	NULL
them	NULL
was	NULL
capable	NULL
of	NULL
neutralizing	NULL
TCM	NULL
effects	NULL
(	NULL
Hsieh	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

Based	NULL
on	NULL
semipurification	NULL
of	NULL
growth-modulatory	NULL
activity	NULL
.	NULL

it	NULL
was	NULL
proposed	NULL
that	NULL
a	NULL
protein	NULL
in	NULL
the	NULL
molecular	NULL
weight	NULL
range	NULL
of	NULL
13-24	NULL
kDa	NULL
is	NULL
responsible	NULL
for	NULL
TCM	NULL
action	NULL
.	NULL

It	NULL
is	NULL
not	NULL
unlikely	NULL
that	NULL
©	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
1998	NULL
growth-modulatory	NULL
effects	NULL
of	NULL
TCM	NULL
and	NULL
MCM	NULL
could	NULL
be	NULL
.	NULL

at	NULL
least	NULL
in	NULL
part	NULL
.	NULL

attributed	NULL
to	NULL
the	NULL
same	NULL
cytokine	NULL
.	NULL

Monocytes	NULL
are	NULL
known	NULL
as	NULL
the	NULL
major	NULL
source	NULL
of	NULL
secreted	NULL
IL-1	NULL
(	NULL
Dinarello	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

Human	NULL
IL-1	NULL
}	NULL
is	NULL
a	NULL
17-kDa	NULL
protein	NULL
that	NULL
is	NULL
secreted	NULL
during	NULL
an	NULL
inflammatory	NULL
process	NULL
.	NULL

Two	NULL
functionally	NULL
almost	NULL
equivalent	NULL
forms	NULL
of	NULL
IL-1	NULL
.	NULL

IL-1a	NULL
@	NULL
and	NULL
IL-1B	NULL
.	NULL

which	NULL
display	NULL
about	NULL
27	NULL
%	NULL
homology	NULL
at	NULL
the	NULL
protein	NULL
level	NULL
.	NULL

exist	NULL
.	NULL

Both	NULL
forms	NULL
of	NULL
IL-1	NULL
bind	NULL
to	NULL
the	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
78	NULL
(	NULL
8	NULL
)	NULL
.	NULL

1004-1011	NULL
1010	NULL
Z	NULL
Culig	NULL
et	NULL
al	NULL
same	NULL
cell-surface	NULL
receptor	NULL
and	NULL
therefore	NULL
show	NULL
similar	NULL
biological	NULL
activities	NULL
.	NULL

IL-1	NULL
was	NULL
found	NULL
to	NULL
exhibit	NULL
anti-tumour	NULL
activity	NULL
in	NULL
various	NULL
neoplasms	NULL
either	NULL
by	NULL
augmentation	NULL
of	NULL
cellular	NULL
immune	NULL
response	NULL
or	NULL
by	NULL
inhibition	NULL
of	NULL
proliferation	NULL
(	NULL
Braunschweiger	NULL
et	NULL
al	NULL
.	NULL

1988	NULL
:	NULL
Kilian	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
our	NULL
results	NULL
.	NULL

IL-1	NULL
was	NULL
previously	NULL
found	NULL
to	NULL
provoke	NULL
a	NULL
dose-dependent	NULL
growth	NULL
inhibition	NULL
in	NULL
LNCaP	NULL
cells	NULL
(	NULL
Hsieh	NULL
and	NULL
Chiao	NULL
.	NULL

1995	NULL
;	NULL
Ritchie	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

IL-1	NULL
diminished	NULL
DHT	NULL
effect	NULL
on	NULL
the	NULL
proportion	NULL
of	NULL
the	NULL
replicating	NULL
LNCaP	NULL
cells	NULL
(	NULL
Hsieh	NULL
and	NULL
Chiao	NULL
.	NULL

1995	NULL
)	NULL
.	NULL

However	NULL
.	NULL

our	NULL
results	NULL
with	NULL
regard	NULL
to	NULL
AR	NULL
binding	NULL
differ	NULL
from	NULL
those	NULL
of	NULL
Hsieh	NULL
and	NULL
Chiao	NULL
.	NULL

These	NULL
authors	NULL
failed	NULL
to	NULL
show	NULL
a	NULL
negative	NULL
effect	NULL
on	NULL
AR	NULL
protein	NULL
levels	NULL
after	NULL
IL-1	NULL
&	NULL
treatment	NULL
.	NULL

Ritchie	NULL
et	NULL
al	NULL
(	NULL
1997	NULL
)	NULL
also	NULL
treated	NULL
LNCaP	NULL
cells	NULL
and	NULL
androgen-independent	NULL
PC-3	NULL
and	NULL
DU-145	NULL
cells	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
IL-1B	NULL
.	NULL

Supplementation	NULL
of	NULL
prostate	NULL
cell	NULL
cultures	NULL
with	NULL
IL-1B	NULL
caused	NULL
a	NULL
decreased	NULL
proliferation	NULL
of	NULL
all	NULL
three	NULL
cell	NULL
lines	NULL
.	NULL

However	NULL
.	NULL

the	NULL
negative	NULL
effect	NULL
of	NULL
IL-1f	NULL
on	NULL
proliferation	NULL
was	NULL
far	NULL
more	NULL
pronounced	NULL
in	NULL
LNCaP	NULL
cells	NULL
than	NULL
in	NULL
the	NULL
two	NULL
androgen-independent	NULL
cell	NULL
lines	NULL
.	NULL

Although	NULL
determination	NULL
of	NULL
AR	NULL
protein	NULL
was	NULL
not	NULL
performed	NULL
in	NULL
that	NULL
study	NULL
.	NULL

a	NULL
marked	NULL
effect	NULL
in	NULL
LNCaP	NULL
cells	NULL
suggests	NULL
an	NULL
interaction	NULL
between	NULL
IL-1	NULL
B	NULL
and	NULL
AR	NULL
pathways	NULL
.	NULL

IL-1	NULL
B	NULL
also	NULL
decreased	NULL
cell	NULL
chemo-taxis	NULL
in	NULL
the	NULL
three	NULL
prostate	NULL
cancer	NULL
cell	NULL
lines	NULL
(	NULL
Ritchie	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Interestingly	NULL
.	NULL

inhibition	NULL
of	NULL
growth	NULL
of	NULL
MCF-7	NULL
breast	NULL
cancer	NULL
cells	NULL
by	NULL
IL-1	NULL
is	NULL
associated	NULL
with	NULL
down-regulation	NULL
of	NULL
oestrogen	NULL
receptor	NULL
(	NULL
Danforth	NULL
and	NULL
Sgagias	NULL
.	NULL

1991	NULL
)	NULL
.	NULL

A	NULL
different	NULL
type	NULL
of	NULL
interaction	NULL
between	NULL
monocytes	NULL
and	NULL
LNCaP	NULL
cells	NULL
was	NULL
recently	NULL
reported	NULL
(	NULL
Klein	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
matrilysin	NULL
.	NULL

which	NULL
is	NULL
a	NULL
member	NULL
of	NULL
the	NULL
matrix	NULL
metalloproteinase	NULL
superfamily	NULL
.	NULL

in	NULL
LNCaP	NULL
cells	NULL
is	NULL
induced	NULL
by	NULL
conditioned	NULL
medium	NULL
from	NULL
the	NULL
monocytic	NULL
cell	NULL
line	NULL
THP-1	NULL
.	NULL

In	NULL
addition	NULL
.	NULL

recombinant	NULL
IL-1	NULL
up-regulated	NULL
-	NULL
matrilysin	NULL
expression	NULL
.	NULL

Biological	NULL
neutralization	NULL
experiments	NULL
revealed	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
THP-1	NULL
conditioned	NULL
medium	NULL
was	NULL
abolished	NULL
by	NULL
an	NULL
anti-IL-	NULL
1	NULL
B	NULL
antibody	NULL
.	NULL

and	NULL
it	NULL
was	NULL
concluded	NULL
that	NULL
IL-1	NULL
f	NULL
is	NULL
a	NULL
mediator	NULL
of	NULL
matrilysin	NULL
induction	NULL
.	NULL

This	NULL
up-regulation	NULL
of	NULL
matrilysin	NULL
by	NULL
IL-1	NULL
may	NULL
be	NULL
harmful	NULL
in	NULL
prostate	NULL
cancer	NULL
.	NULL

It	NULL
was	NULL
shown	NULL
that	NULL
matrilysin-transfected	NULL
prostate	NULL
cancer	NULL
cells	NULL
have	NULL
a	NULL
high	NULL
invasive	NULL
potential	NULL
in	NULL
immunodeficient	NULL
mice	NULL
(	NULL
Powell	NULL
et	NULL
al	NULL
.	NULL

1993	NULL
)	NULL
.	NULL

IL-1	NULL
}	NULL
activates	NULL
several	NULL
second-messenger	NULL
systems	NULL
in	NULL
target	NULL
tissues	NULL
(	NULL
Munoz	NULL
et	NULL
al	NULL
.	NULL

1990	NULL
;	NULL
Roberts	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
:	NULL
Carman-Krzan	NULL
and	NULL
Wise	NULL
.	NULL

1993	NULL
;	NULL
Cole	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
:	NULL
Sjoholm	NULL
1995	NULL
)	NULL
.	NULL

For	NULL
example	NULL
.	NULL

IL-	NULL
1B	NULL
induces	NULL
cAMP	NULL
in	NULL
human	NULL
decidual	NULL
cells	NULL
.	NULL

It	NULL
stimulates	NULL
secretion	NULL
of	NULL
nerve	NULL
growth	NULL
factor	NULL
in	NULL
astroglial	NULL
cultures	NULL
by	NULL
activation	NULL
of	NULL
the	NULL
phospholipase	NULL
A2-lipoxygenase	NULL
pathway	NULL
.	NULL

In	NULL
pancreatic	NULL
B-cells	NULL
ceramide	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
transducing	NULL
the	NULL
cytotoxic	NULL
and	NULL
cyto-static	NULL
actions	NULL
of	NULL
IL-1B	NULL
.	NULL

Involvement	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
nitric	NULL
oxide	NULL
pathways	NULL
in	NULL
IL-1B	NULL
signalling	NULL
was	NULL
also	NULL
described	NULL
.	NULL

It	NULL
remains	NULL
to	NULL
be	NULL
determined	NULL
in	NULL
future	NULL
studies	NULL
which	NULL
of	NULL
these	NULL
signalling	NULL
pathways	NULL
may	NULL
be	NULL
operative	NULL
in	NULL
prostatic	NULL
epithelial	NULL
cells	NULL
.	NULL

In	NULL
summary	NULL
.	NULL

this	NULL
study	NULL
demonstrates	NULL
that	NULL
the	NULL
monocyte	NULL
secretory	NULL
product	NULL
IL-1	NULL
}	NULL
is	NULL
a	NULL
potentially	NULL
important	NULL
negative	NULL
regulator	NULL
in	NULL
LNCaP	NULL
cells	NULL
.	NULL

Therapeutic	NULL
application	NULL
of	NULL
this	NULL
pleiotropic	NULL
cytokine	NULL
in	NULL
prostate	NULL
cancer	NULL
will	NULL
probably	NULL
be	NULL
further	NULL
explored	NULL
.	NULL

ACKNOWLEDGEMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
SFB	NULL
002	NULL
F203	NULL
and	NULL
P	NULL
10	NULL
132-MED	NULL
of	NULL
the	NULL
Austrian	NULL
Science	NULL
Foundation	NULL
(	NULL
FWF	NULL
)	NULL
.	NULL

The	NULL
excellent	NULL
technical	NULL
assistance	NULL
of	NULL
G	NULL
Sierek	NULL
.	NULL

H	NULL
Linnert	NULL
.	NULL

G	NULL
Holz	NULL
]	NULL
.	NULL

E	NULL
Tafatsch	NULL
.	NULL

M	NULL
Karches-Bohm	NULL
and	NULL
P	NULL
Dertschnig	NULL
and	NULL
the	NULL
editorial	NULL
assistance	NULL
of	NULL
M.	NULL
Trebo	NULL
.	NULL

K.	NULL
Smekal	NULL
and	NULL
M.	NULL
Neuhauser	NULL
are	NULL
gratefully	NULL
acknowledged	NULL
.	NULL

British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
78	NULL
(	NULL
8	NULL
)	NULL
.	NULL

1004-1011	NULL
REFERENCES	NULL
Bang	NULL
YJ	NULL
.	NULL

Pimia	NULL
F.	NULL
Fang	NULL
WG	NULL
.	NULL

Kang	NULL
WK	NULL
.	NULL

Sartor	NULL
O.	NULL
Whitesell	NULL
L.	NULL
Ha	NULL
MJ	NULL
.	NULL

Tsoko~	NULL
M.	NULL
Sheahan	NULL
MD	NULL
.	NULL

Nguyen	NULL
P.	NULL
Niklinski	NULL
WT	NULL
.	NULL

Myers	NULL
CE	NULL
and	NULL
Trepel	NULL
JB	NULL
(	NULL
1994	NULL
;	NULL
Terminal	NULL
neuroendocrine	NULL
differentiation	NULL
of	NULL
human	NULL
prostate	NULL
carcinoma	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
intracellular	NULL
cyclic	NULL
AMP	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sei	NULL
USA	NULL
91	NULL
:	NULL
5330-5334	NULL
Bradford	NULL
M	NULL
(	NULL
1978	NULL
)	NULL
A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
using	NULL
the	NULL
principle	NULL
of	NULL
protein-dye	NULL
binding	NULL
.	NULL

Anal	NULL
Biochem	NULL
72	NULL
:	NULL
248-254	NULL
Braunschweiger	NULL
PG	NULL
.	NULL

Johnson	NULL
CS	NULL
.	NULL

Kumar	NULL
N.	NULL
Ord	NULL
V	NULL
and	NULL
Furmanski	NULL
P	NULL
(	NULL
1988	NULL
)	NULL
Antitumor	NULL
effects	NULL
of	NULL
recombinant	NULL
human	NULL
interleukin	NULL
1	NULL
alpha	NULL
in	NULL
RIF-1	NULL
and	NULL
Pane02	NULL
solid	NULL
tumors	NULL
.	NULL

Cancer	NULL
Res	NULL
48	NULL
:	NULL
6011-6016	NULL
Carman-Krzan	NULL
M	NULL
and	NULL
Wise	NULL
BC	NULL
(	NULL
1993	NULL
)	NULL
Arachidonic	NULL
acid	NULL
lipoxygenation	NULL
may	NULL
mediate	NULL
interleukin-1	NULL
stimulation	NULL
of	NULL
nerve	NULL
growth	NULL
factor	NULL
secretion	NULL
in	NULL
astroglial	NULL
cultures	NULL
.	NULL

J	NULL
Neurosci	NULL
Res	NULL
34	NULL
:	NULL
225-232	NULL
Cole	NULL
OF	NULL
.	NULL

Seki	NULL
H.	NULL
Elder	NULL
MG.	NULL
Sullivan	NULL
MHF	NULL
(	NULL
1995	NULL
)	NULL
Interleukin-1	NULL
f	NULL
independently	NULL
stimulates	NULL
production	NULL
of	NULL
prostaglandin	NULL
E2	NULL
and	NULL
cyclic	NULL
AMP	NULL
from	NULL
human	NULL
decidual	NULL
cells	NULL
.	NULL

Biochim	NULL
Biophys	NULL
Acta	NULL
1269	NULL
;	NULL
139-144	NULL
Cronauer	NULL
MV	NULL
.	NULL

Klocker	NULL
H.	NULL
Talasz	NULL
H.	NULL
Geisen	NULL
F.	NULL
Hobisch	NULL
A.	NULL
Radmayr	NULL
C.	NULL
Bock	NULL
G.	NULL
Culig	NULL
Z.	NULL
Schirmer	NULL
M.	NULL
Reissigl	NULL
A.	NULL
Bartsch	NULL
G.	NULL
Konwalinka	NULL
G	NULL
(	NULL
1996	NULL
)	NULL
Inhibitory	NULL
effects	NULL
of	NULL
the	NULL
nucleoside	NULL
analogue	NULL
gemcitabine	NULL
on	NULL
prostatic	NULL
carcinoma	NULL
cells	NULL
.	NULL

Prostate	NULL
28	NULL
:	NULL
172-181	NULL
Culig	NULL
Z.	NULL
Hobisch	NULL
A.	NULL
Cronauer	NULL
MV	NULL
.	NULL

Cato	NULL
ACB	NULL
.	NULL

Hittmair	NULL
A.	NULL
Radmayt	NULL
C.	NULL
Eberie	NULL
J.	NULL
Bartsch	NULL
G.	NULL
Klocker	NULL
H	NULL
(	NULL
1993	NULL
;	NULL
Mutant	NULL
androgen	NULL
receptor	NULL
detected	NULL
in	NULL
an	NULL
ady	NULL
anced-stage	NULL
prostatic	NULL
carcinoma	NULL
is	NULL
activated	NULL
by	NULL
adrenal	NULL
androgens	NULL
and	NULL
progesterone	NULL
.	NULL

Mo	NULL
!	NULL

Endocrinol	NULL
7	NULL
:	NULL
1341-1550	NULL
Culig	NULL
Z.	NULL
Hobisch	NULL
A.	NULL
Cronauer	NULL
MV	NULL
,	NULL
Radmayr	NULL
C.	NULL
Trapman	NULL
J.	NULL
Hittmair	NULL
A.	NULL
Bartsch	NULL
G.	NULL
Klocker	NULL
H	NULL
(	NULL
1994	NULL
)	NULL
Androgen	NULL
receptor	NULL
activation	NULL
in	NULL
prostatic	NULL
tumor	NULL
cell	NULL
lines	NULL
by	NULL
insulin-like	NULL
growth	NULL
factor-I	NULL
.	NULL

keratinocyte	NULL
grow	NULL
th	NULL
factor	NULL
and	NULL
epidermal	NULL
growth	NULL
factor	NULL
.	NULL

Cancer	NULL
Res	NULL
54	NULL
:	NULL
5474-5478	NULL
Curtis	NULL
BM	NULL
.	NULL

Gallis	NULL
B.	NULL
Overell	NULL
RW	NULL
.	NULL

McMahan	NULL
CJ	NULL
.	NULL

deRoon	NULL
P.	NULL
Ireland	NULL
R.	NULL
Eisenman	NULL
J.	NULL
Dower	NULL
SK	NULL
.	NULL

Sims	NULL
JE	NULL
(	NULL
1989	NULL
)	NULL
T-cell	NULL
interleukin	NULL
1	NULL
receptor	NULL
cDNA	NULL
expressed	NULL
in	NULL
Chinese	NULL
hamster	NULL
ovary	NULL
cells	NULL
regulates	NULL
functional	NULL
responses	NULL
to	NULL
interleukin	NULL
1	NULL
.	NULL

Proc	NULL
Natl	NULL
Acad	NULL
Sci	NULL
USA	NULL
86	NULL
:	NULL
3045-3049	NULL
Dalkin	NULL
AC	NULL
.	NULL

Gilrain	NULL
JT	NULL
.	NULL

Bradshaw	NULL
D.	NULL
Myers	NULL
CE	NULL
(	NULL
1996	NULL
)	NULL
Activin	NULL
inhibition	NULL
of	NULL
prostate	NULL
cancer	NULL
cell	NULL
growth	NULL
:	NULL
selective	NULL
actions	NULL
on	NULL
androgen-responsive	NULL
LNCaP	NULL
cells	NULL
.	NULL

Endocrinology	NULL
137	NULL
;	NULL
5230-5235	NULL
Danforth	NULL
DN	NULL
Jr	NULL
and	NULL
Sgagias	NULL
MK	NULL
(	NULL
1991	NULL
)	NULL
Interleukin	NULL
1	NULL
alpha	NULL
blocks	NULL
estradiol-stimulated	NULL
growth	NULL
and	NULL
down-regulates	NULL
the	NULL
estrogen	NULL
receptor	NULL
in	NULL
MCF-7	NULL
breast	NULL
cancer	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

Cancer	NULL
Res	NULL
S1	NULL
:	NULL
1488-1493	NULL
Dinarello	NULL
CA	NULL
(	NULL
1988	NULL
)	NULL
Biology	NULL
of	NULL
interleukin	NULL
1	NULL
.	NULL

FASEB	NULL
J	NULL
2	NULL
:	NULL
108-115	NULL
Esxquenet	NULL
M.	NULL
Sw	NULL
innen	NULL
JV	NULL
.	NULL

Heyns	NULL
W.	NULL
Verhoeven	NULL
G	NULL
(	NULL
1995	NULL
)	NULL
Triiodothy	NULL
ronine	NULL
modulates	NULL
growth	NULL
.	NULL

secretory	NULL
function	NULL
and	NULL
androgen	NULL
receptor	NULL
concentration	NULL
in	NULL
the	NULL
prostatic	NULL
carcinoma	NULL
cell	NULL
line	NULL
LNCaP	NULL
.	NULL

Mo	NULL
?	NULL

Cell	NULL
Endocrinol	NULL
109	NULL
:	NULL
105-111	NULL
Fong	NULL
CJ	NULL
.	NULL

Sutkow	NULL
ski	NULL
DM	NULL
.	NULL

Braun	NULL
EJ	NULL
.	NULL

Bauer	NULL
KD	NULL
.	NULL

Sherw	NULL
ood	NULL
ER	NULL
.	NULL

Lee	NULL
C.	NULL
Kozlow	NULL
ski	NULL
JM	NULL
(	NULL
1993	NULL
;	NULL
Effect	NULL
of	NULL
retinoic	NULL
acid	NULL
on	NULL
the	NULL
proliferation	NULL
and	NULL
secretory	NULL
activity	NULL
of	NULL
androgen-responsive	NULL
prostatic	NULL
carcinoma	NULL
cells	NULL
.	NULL

J	NULL
Uro	NULL
{	NULL
149	NULL
:	NULL
1190-1194	NULL
Hobisch	NULL
A.	NULL
Culig	NULL
Z.	NULL
Radmayr	NULL
C.	NULL
Bartsch	NULL
G.	NULL
Klocker	NULL
H.	NULL
Hittmair	NULL
A	NULL
(	NULL
1995	NULL
)	NULL
Distant	NULL
metastases	NULL
from	NULL
human	NULL
prostatic	NULL
carcinoma	NULL
express	NULL
androgen	NULL
receptor	NULL
protein	NULL
Cancer	NULL
Res	NULL
55	NULL
:	NULL
3068-3072	NULL
Hobisch	NULL
A.	NULL
Culig	NULL
Z.	NULL
Radmayr	NULL
C.	NULL
Bartsch	NULL
G.	NULL
Klocker	NULL
H.	NULL
Hinumair	NULL
A	NULL
+1996	NULL
)	NULL
Androgen	NULL
receptor	NULL
status	NULL
of	NULL
lymph	NULL
node	NULL
metastases	NULL
from	NULL
prostate	NULL
cancer	NULL
.	NULL

Prostate	NULL
28	NULL
:	NULL
129-1	NULL
35	NULL
Horoszewicz	NULL
JS	NULL
.	NULL

Leong	NULL
SS	NULL
.	NULL

Kaw	NULL
inski	NULL
E.	NULL
Karr	NULL
JP	NULL
.	NULL

Rosenthal	NULL
H.	NULL
Chu	NULL
TM	NULL
.	NULL

Mirand	NULL
EA	NULL
.	NULL

Murphy	NULL
GP	NULL
(	NULL
1983	NULL
)	NULL
LNCaP	NULL
model	NULL
of	NULL
human	NULL
prostatic	NULL
carcinoma	NULL
.	NULL

Cancer	NULL
Res	NULL
43	NULL
:	NULL
1809-1819	NULL
Hsieh	NULL
TC	NULL
and	NULL
Chiao	NULL
JW	NULL
(	NULL
1995	NULL
)	NULL
Growth	NULL
modulation	NULL
of	NULL
human	NULL
prostatic	NULL
cancer	NULL
cells	NULL
by	NULL
interleukin-1	NULL
and	NULL
interleukin-1	NULL
receptor	NULL
antagonist	NULL
.	NULL

Cancer	NULL
Lert	NULL
95	NULL
:	NULL
119-123	NULL
Hsieh	NULL
TC	NULL
.	NULL

Xu	NULL
W.	NULL
Chiao	NULL
JW	NULL
(	NULL
1995	NULL
)	NULL
Growth	NULL
regulation	NULL
and	NULL
cellular	NULL
changes	NULL
during	NULL
differentiation	NULL
of	NULL
human	NULL
prostatic	NULL
cancer	NULL
LNCaP	NULL
cells	NULL
as	NULL
induced	NULL
by	NULL
T	NULL
Iymphocyte-conditioned	NULL
medium	NULL
.	NULL

£xp	NULL
Cell	NULL
Res	NULL
218	NULL
:	NULL
137-143	NULL
Iversen	NULL
PO	NULL
.	NULL

Hart	NULL
PH	NULL
.	NULL

Bonder	NULL
CS	NULL
.	NULL

Lopez	NULL
AF	NULL
(	NULL
1997	NULL
)	NULL
Interleukin	NULL
(	NULL
IL	NULL
+-10	NULL
.	NULL

but	NULL
not	NULL
IL-4	NULL
or	NULL
IL-13	NULL
.	NULL

inhibits	NULL
cytokine	NULL
production	NULL
and	NULL
grow	NULL
th	NULL
in	NULL
juvenile	NULL
myelomonocytic	NULL
leukemia	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
87	NULL
;	NULL
476-180	NULL
Kallio	NULL
PJ	NULL
.	NULL

Janne	NULL
OA	NULL
.	NULL

Palvimo	NULL
JJ	NULL
(	NULL
1994	NULL
)	NULL
Agonists	NULL
.	NULL

but	NULL
not	NULL
antagonists	NULL
.	NULL

alter	NULL
the	NULL
conformation	NULL
of	NULL
the	NULL
hormone-binding	NULL
domain	NULL
of	NULL
the	NULL
androgen	NULL
receptor	NULL
.	NULL

Endocrinology	NULL
134	NULL
;	NULL
998-1001	NULL
Kemppainen	NULL
JA	NULL
.	NULL

Lane	NULL
MV	NULL
.	NULL

Sar	NULL
M.	NULL
Wilson	NULL
EM	NULL
(	NULL
1992	NULL
)	NULL
Androgen	NULL
receptor	NULL
phosphorylation	NULL
.	NULL

turnover	NULL
.	NULL

nuclear	NULL
transport	NULL
.	NULL

and	NULL
transcriptional	NULL
activation	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
267	NULL
:	NULL
968-974	NULL
Kilian	NULL
PL	NULL
.	NULL

Kaffka	NULL
KL	NULL
.	NULL

Biondi	NULL
DA	NULL
.	NULL

Lipman	NULL
JA	NULL
.	NULL

Benjamin	NULL
WR	NULL
.	NULL

Feldman	NULL
D.	NULL
Campen	NULL
CA	NULL
(	NULL
1991	NULL
)	NULL
Antiproliferative	NULL
effect	NULL
of	NULL
interleukin-1	NULL
on	NULL
human	NULL
ovarian	NULL
carcinoma	NULL
cell	NULL
line	NULL
(	NULL
NIH	NULL
:	NULL
OVCAR-3	NULL
)	NULL
.	NULL

Cancer	NULL
Res	NULL
51	NULL
:	NULL
1823-1828	NULL
©	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
1998	NULL
Kim	NULL
IY	NULL
.	NULL

Kim	NULL
JH	NULL
.	NULL

Zeiner	NULL
DJ	NULL
.	NULL

Ahn	NULL
HJ	NULL
.	NULL

Sensibar	NULL
JA	NULL
.	NULL

Lee	NULL
C	NULL
(	NULL
1996	NULL
)	NULL
Transforming	NULL
growth	NULL
factor-beta	NULL
1	NULL
is	NULL
a	NULL
mediator	NULL
of	NULL
androgen-regulated	NULL
growth	NULL
arrest	NULL
in	NULL
an	NULL
androgen-responsive	NULL
prostatic	NULL
cancer	NULL
cell	NULL
line	NULL
.	NULL

LNCaP	NULL
.	NULL

Endocrinology	NULL
137	NULL
;	NULL
991-999	NULL
Klein	NULL
RD	NULL
.	NULL

Borchers	NULL
AH	NULL
.	NULL

Sundareshan	NULL
P.	NULL
Bougelet	NULL
C.	NULL
Berkman	NULL
MR.	NULL
Nagle	NULL
RB	NULL
.	NULL

Bowden	NULL
GT	NULL
(	NULL
1997	NULL
)	NULL
Interleukin-1	NULL
B	NULL
secreted	NULL
from	NULL
monocytic	NULL
cells	NULL
induces	NULL
the	NULL
expression	NULL
of	NULL
matrilysin	NULL
in	NULL
the	NULL
prostatic	NULL
cell	NULL
line	NULL
LNCaP	NULL
.	NULL

J	NULL
Bio/	NULL
Chem	NULL
272	NULL
;	NULL
14188-14192	NULL
Kokontis	NULL
J.	NULL
Takakura	NULL
K.	NULL
Hay	NULL
N.	NULL
Liao	NULL
S	NULL
(	NULL
1994	NULL
)	NULL
Increased	NULL
androgen	NULL
receptor	NULL
activity	NULL
and	NULL
altered	NULL
c-myc	NULL
expression	NULL
in	NULL
prostate	NULL
cancer	NULL
cells	NULL
after	NULL
long-term	NULL
androgen	NULL
deprivation	NULL
.	NULL

Cancer	NULL
Res	NULL
54	NULL
:	NULL
1566-1573	NULL
Lee	NULL
C.	NULL
Sutkowski	NULL
DM	NULL
.	NULL

Sensibar	NULL
JA	NULL
.	NULL

Zeiner	NULL
D.	NULL
Kim	NULL
I.	NULL
Amsel	NULL
I.	NULL
Shaw	NULL
N.	NULL
Prins	NULL
GS	NULL
.	NULL

Kozlowski	NULL
JM	NULL
(	NULL
1995	NULL
)	NULL
Regulation	NULL
of	NULL
proliferation	NULL
and	NULL
production	NULL
of	NULL
prostate-specific	NULL
antigen	NULL
in	NULL
androgen-sensitive	NULL
prostate	NULL
cancer	NULL
cells	NULL
.	NULL

LNCaP	NULL
.	NULL

by	NULL
dihydrotestosterone	NULL
.	NULL

Endocrinology	NULL
136	NULL
:	NULL
796-805	NULL
Limonta	NULL
P.	NULL
Dondi	NULL
D.	NULL
Moretti	NULL
RM	NULL
.	NULL

Maggi	NULL
R.	NULL
Motta	NULL
M	NULL
(	NULL
1992	NULL
)	NULL
Antiproliferative	NULL
effects	NULL
of	NULL
luteinizing	NULL
hormone-releasing	NULL
hormone	NULL
agonists	NULL
on	NULL
the	NULL
human	NULL
prostatic	NULL
cancer	NULL
cell	NULL
line	NULL
LNCaP	NULL
.	NULL

J	NULL
Clin	NULL
Endocrinol	NULL
Metab	NULL
75	NULL
:	NULL
207-212	NULL
Lisak	NULL
RP	NULL
and	NULL
Bealmear	NULL
B	NULL
(	NULL
1991	NULL
)	NULL
Antibodies	NULL
to	NULL
interleukin-1	NULL
inhibit	NULL
cytokine-induced	NULL
proliferation	NULL
of	NULL
neonatal	NULL
rat	NULL
Schwann	NULL
cells	NULL
in	NULL
vitro	NULL
.	NULL

J	NULL
Neurvimmunol	NULL
31	NULL
:	NULL
123-132	NULL
MacDonald	NULL
A	NULL
and	NULL
Habib	NULL
FK	NULL
(	NULL
1992	NULL
)	NULL
Divergent	NULL
responses	NULL
to	NULL
epidermal	NULL
growth	NULL
factor	NULL
in	NULL
hormone	NULL
sensitive	NULL
and	NULL
insensitive	NULL
human	NULL
prostate	NULL
cancer	NULL
cell	NULL
lines	NULL
.	NULL

Br	NULL
J	NULL
Cancer	NULL
65	NULL
:	NULL
177-182	NULL
Munoz	NULL
E.	NULL
Bentner	NULL
U.	NULL
Zubiaga	NULL
A.	NULL
Huber	NULL
BT	NULL
(	NULL
1990	NULL
)	NULL
IL-1	NULL
activates	NULL
two	NULL
separate	NULL
signal	NULL
transduction	NULL
pathways	NULL
in	NULL
T	NULL
helper	NULL
type	NULL
II	NULL
cells	NULL
.	NULL

J	NULL
immuno	NULL
!	NULL

144	NULL
:	NULL
964-969	NULL
Nakamoto	NULL
T.	NULL
Chang	NULL
C.	NULL
Li	NULL
A.	NULL
Chodak	NULL
GW	NULL
(	NULL
1992	NULL
)	NULL
Basic	NULL
fibroblast	NULL
growth	NULL
factor	NULL
in	NULL
human	NULL
prostate	NULL
cancer	NULL
cells	NULL
.	NULL

Cancer	NULL
Res	NULL
52	NULL
:	NULL
571-577	NULL
Nazareth	NULL
LV	NULL
and	NULL
Weigel	NULL
NL	NULL
(	NULL
1996	NULL
)	NULL
Activation	NULL
of	NULL
the	NULL
human	NULL
androgen	NULL
receptor	NULL
through	NULL
protein	NULL
kinase	NULL
A	NULL
signaling	NULL
pathway	NULL
.	NULL

J	NULL
Bio/	NULL
Chem	NULL
271	NULL
:	NULL
19900-19907	NULL
Noordzi	NULL
;	NULL
MA	NULL
.	NULL

van	NULL
Weerden	NULL
WM	NULL
.	NULL

de	NULL
Ridder	NULL
CM	NULL
.	NULL

van	NULL
der	NULL
Kwast	NULL
TH	NULL
.	NULL

Schroder	NULL
FH	NULL
.	NULL

van	NULL
Steenbrugge	NULL
GJ	NULL
(	NULL
1996	NULL
)	NULL
Neuroendocrine	NULL
differentiation	NULL
in	NULL
human	NULL
prostatic	NULL
turnor	NULL
models	NULL
.	NULL

Am	NULL
J	NULL
Pathol	NULL
149	NULL
;	NULL
859-871	NULL
Peeh	NULL
]	NULL
DM	NULL
.	NULL

Wong	NULL
ST.	NULL
Stamey	NULL
TA	NULL
(	NULL
1993	NULL
)	NULL
Vitamin	NULL
A	NULL
regulates	NULL
proliferation	NULL
and	NULL
differentiation	NULL
of	NULL
human	NULL
prostatic	NULL
epithelial	NULL
cells	NULL
.	NULL

Prostate	NULL
23	NULL
:	NULL
69-78	NULL
Powell	NULL
WC	NULL
.	NULL

Knox	NULL
JD	NULL
.	NULL

Navre	NULL
M.	NULL
Grogan	NULL
TM	NULL
.	NULL

Kittelson	NULL
J.	NULL
Nagle	NULL
RB	NULL
.	NULL

Bowden	NULL
GT	NULL
(	NULL
1993	NULL
)	NULL
Expression	NULL
of	NULL
the	NULL
metalloproteinase	NULL
matrilysin	NULL
in	NULL
DU-145	NULL
cells	NULL
increases	NULL
their	NULL
invasive	NULL
potential	NULL
in	NULL
severe	NULL
combined	NULL
immunodeficient	NULL
mice	NULL
.	NULL

Cancer	NULL
Res	NULL
53	NULL
:	NULL
417-422	NULL
Ritchie	NULL
CK	NULL
.	NULL

Andrews	NULL
LE	NULL
.	NULL

Thomas	NULL
KG	NULL
.	NULL

Tindall	NULL
DJ	NULL
.	NULL

Fitzpatrick	NULL
LA	NULL
(	NULL
1997	NULL
)	NULL
The	NULL
effects	NULL
of	NULL
growth	NULL
factors	NULL
associated	NULL
with	NULL
osteoblasts	NULL
on	NULL
prostate	NULL
carcinoma	NULL
proliferation	NULL
and	NULL
chemotaxis	NULL
:	NULL
implications	NULL
for	NULL
the	NULL
development	NULL
of	NULL
metastatic	NULL
disease	NULL
.	NULL

Endocrinology	NULL
138	NULL
:	NULL
1145-1150	NULL
©	NULL
Cancer	NULL
Research	NULL
Campaign	NULL
1998	NULL
effects	NULL
on	NULL
prostate	NULL
tumour	NULL
cells	NULL
1011	NULL
Roberts	NULL
AB	NULL
.	NULL

Vodovotz	NULL
Y.	NULL
Roche	NULL
NS	NULL
.	NULL

Sporn	NULL
MB	NULL
.	NULL

Nathan	NULL
CF	NULL
(	NULL
1992	NULL
)	NULL
Role	NULL
of	NULL
nitric	NULL
oxide	NULL
in	NULL
antagonistic	NULL
effects	NULL
of	NULL
TGFBI	NULL
and	NULL
interleukin	NULL
1B	NULL
on	NULL
the	NULL
beating	NULL
rate	NULL
of	NULL
cultured	NULL
cardiac	NULL
miocytes	NULL
.	NULL

Mol	NULL
Endocrinol	NULL
6	NULL
:	NULL
1921-1930	NULL
Salem	NULL
P.	NULL
Deryckx	NULL
S.	NULL
Dutioust	NULL
A.	NULL
Vivier	NULL
E.	NULL
Denizot	NULL
Y.	NULL
Damais	NULL
C.	NULL
Dinarello	NULL
CA	NULL
.	NULL

Thomas	NULL
Y	NULL
(	NULL
1990	NULL
)	NULL
Immunoregulatory	NULL
functions	NULL
of	NULL
paf-acether	NULL
.	NULL

IV	NULL
.	NULL

Enhancement	NULL
of	NULL
IL-1	NULL
production	NULL
by	NULL
muramyl	NULL
dipeptide-stimulated	NULL
monocytes	NULL
.	NULL

J	NULL
Immunol	NULL
144	NULL
;	NULL
1338-134	NULL
Sjohoim	NULL
A	NULL
(	NULL
1995	NULL
)	NULL
Ceramide	NULL
inhibits	NULL
pancreatic	NULL
B-cell	NULL
insulin	NULL
production	NULL
and	NULL
mitogenesis	NULL
and	NULL
mimics	NULL
the	NULL
actions	NULL
of	NULL
interleukin-1B	NULL
.	NULL

FEBS	NULL
Ler	NULL
367	NULL
:	NULL
283-286	NULL
Skowronski	NULL
RJ	NULL
.	NULL

Peehl	NULL
DM	NULL
.	NULL

Feldman	NULL
D	NULL
(	NULL
1993	NULL
)	NULL
Vitamin	NULL
D	NULL
and	NULL
prostate	NULL
cancer	NULL
:	NULL
1.25	NULL
dihydroxyvitamin	NULL
D3	NULL
receptors	NULL
and	NULL
actions	NULL
in	NULL
human	NULL
prostate	NULL
cancer	NULL
cell	NULL
lines	NULL
.	NULL

Endocrinology	NULL
132	NULL
;	NULL
1952-1960	NULL
Van	NULL
der	NULL
Kwast	NULL
TH	NULL
.	NULL

Schalken	NULL
J.	NULL
Ruizeveld	NULL
de	NULL
Winter	NULL
JA	NULL
.	NULL

van	NULL
Vroonhoven	NULL
CCJ	NULL
.	NULL

Mulder	NULL
E.	NULL
Boersma	NULL
W.	NULL
Trapman	NULL
J	NULL
(	NULL
1991	NULL
)	NULL
Androgen	NULL
receptors	NULL
in	NULL
endoctine-therapy	NULL
resistant	NULL
prostate	NULL
cancer	NULL
.	NULL

Int	NULL
J	NULL
Cancer	NULL
48	NULL
:	NULL
189-193	NULL
Veldschoite	NULL
J.	NULL
Ris-Stalpers	NULL
C.	NULL
Kuiper	NULL
GGJM	NULL
.	NULL

Jenster	NULL
G.	NULL
Berrevoets	NULL
C.	NULL
Claassen	NULL
E.	NULL
van	NULL
Rooij	NULL
HCJ	NULL
.	NULL

Trapman	NULL
J.	NULL
Brinkmann	NULL
AO	NULL
,	NULL
Mulder	NULL
EA	NULL
(	NULL
1990	NULL
)	NULL
A	NULL
mutation	NULL
in	NULL
the	NULL
ligand	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
androgen	NULL
receptor	NULL
of	NULL
human	NULL
LNCaP	NULL
cells	NULL
affects	NULL
steroid	NULL
binding	NULL
characteristics	NULL
and	NULL
response	NULL
to	NULL
anti-androgens	NULL
.	NULL

Biochem	NULL
Biophys	NULL
Res	NULL
Commun	NULL
173	NULL
;	NULL
534-540	NULL
Venkataprasad	NULL
N.	NULL
Shiratsuchi	NULL
H.	NULL
Johnson	NULL
JL	NULL
.	NULL

Ellner	NULL
JJ	NULL
(	NULL
1996	NULL
)	NULL
Induction	NULL
of	NULL
prostaglandin	NULL
E2	NULL
by	NULL
human	NULL
monocytes	NULL
infected	NULL
with	NULL
Mycobacterium	NULL
avium	NULL
complex-modulation	NULL
of	NULL
cytokine	NULL
expression	NULL
.	NULL

J	NULL
Infect	NULL
Dis	NULL
174	NULL
:	NULL
806-811	NULL
Walls	NULL
R.	NULL
Thibault	NULL
A.	NULL
Liu	NULL
L.	NULL
Wood	NULL
C.	NULL
Kozlowski	NULL
JM	NULL
.	NULL

Figg	NULL
WD	NULL
.	NULL

Sampson	NULL
ML	NULL
.	NULL

Elin	NULL
RJ	NULL
.	NULL

Samid	NULL
D	NULL
(	NULL
1996	NULL
)	NULL
The	NULL
differentiating	NULL
agent	NULL
phenylacetate	NULL
increases	NULL
prostate-specific	NULL
antigen	NULL
production	NULL
by	NULL
prostate	NULL
cancer	NULL
cells	NULL
.	NULL

Prostate	NULL
29	NULL
:	NULL
177-182	NULL
Wang	NULL
J.	NULL
Huang	NULL
M.	NULL
Lee	NULL
P.	NULL
Komanduri	NULL
K.	NULL
Sharma	NULL
S.	NULL
Chen	NULL
G.	NULL
Dubinett	NULL
SM	NULL
(	NULL
1996	NULL
)	NULL
Interleukin-8	NULL
inhibits	NULL
non-small	NULL
cell	NULL
lung	NULL
cancer	NULL
proliferation	NULL
:	NULL
a	NULL
possible	NULL
role	NULL
for	NULL
regulation	NULL
of	NULL
tumor	NULL
growth	NULL
by	NULL
autocrine	NULL
and	NULL
paracrine	NULL
pathways	NULL
.	NULL

J	NULL
Interferon	NULL
Cytokine	NULL
Res	NULL
16	NULL
:	NULL
53-60	NULL
Wilding	NULL
G.	NULL
Valverius	NULL
E.	NULL
Knabbe	NULL
C.	NULL
Gelmann	NULL
EP	NULL
(	NULL
1989	NULL
)	NULL
Role	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
alpha	NULL
in	NULL
human	NULL
prostate	NULL
cancer	NULL
cell	NULL
growth	NULL
.	NULL

Prostate	NULL
15	NULL
:	NULL
1-12	NULL
Zhao	NULL
X-Y	NULL
.	NULL

Ly	NULL
LH	NULL
.	NULL

Pech	NULL
!	NULL

DM	NULL
.	NULL

Feldman	NULL
D	NULL
(	NULL
1997	NULL
)	NULL
10.25-dihydroxyvitamin	NULL
D3	NULL
actions	NULL
in	NULL
LNCaP	NULL
human	NULL
prostate	NULL
cancer	NULL
cells	NULL
are	NULL
androgen-dependent	NULL
.	NULL

Endocrinology	NULL
138	NULL
:	NULL
3290-3298	NULL
Young	NULL
CY	NULL
.	NULL

Murtha	NULL
PE	NULL
.	NULL

Andrews	NULL
PE	NULL
.	NULL

Lindzey	NULL
JK	NULL
.	NULL

Tindall	NULL
DJ	NULL
(	NULL
1994	NULL
)	NULL
Antagonism	NULL
of	NULL
androgen	NULL
action	NULL
in	NULL
prostate	NULL
tumor	NULL
cells	NULL
by	NULL
retinoic	NULL
acid	NULL
.	NULL

Prostate	NULL
25	NULL
;	NULL
39-15	NULL
Yuan	NULL
S.	NULL
Trachtenberg	NULL
J	NULL
.	NULL

Mills	NULL
GB	NULL
.	NULL

Brown	NULL
TJ	NULL
.	NULL

Xu	NULL
F	NULL
and	NULL
Keating	NULL
A	NULL
(	NULL
1993	NULL
)	NULL
Androgen-induced	NULL
inhibition	NULL
of	NULL
cell	NULL
proliferation	NULL
in	NULL
an	NULL
androgen-insensitive	NULL
prostate	NULL
cancer	NULL
cell	NULL
line	NULL
(	NULL
PC-3	NULL
)	NULL
transfected	NULL
with	NULL
a	NULL
human	NULL
androgen	NULL
receptor	NULL
complementary	NULL
DNA	NULL
.	NULL

Cancer	NULL
Res	NULL
53	NULL
:	NULL
1304-1311	NULL
British	NULL
Journal	NULL
of	NULL
Cancer	NULL
(	NULL
1998	NULL
)	NULL
78	NULL
(	NULL
8	NULL
)	NULL
,	NULL
1004-1011	NULL

